false FY 0001419051

 2023-06-30

 2024-04-15

 us-gaap: NonrelatedPartyMember

 us-gaap: NonrelatedPartyMember

 TSOI:ResNovaBioIncMember

 TSOI:CampbellNeurosciencesIncMember

 srt: ScenarioPreviouslyReportedMember

 srt: RestatementAdjustmentMember

 srt: RevisionOfPriorPeriodReclassificationAdjustmentMember

 srt: ScenarioPreviouslyReportedMember

 srt: RestatementAdjustmentMember

 srt: RevisionOfPriorPeriodReclassificationAdjustmentMember

 us-gaap: LandMember

 us-gaap: LandMember

 us-gaap: VehiclesMember

 us-gaap: VehiclesMember

 us-gaap: ComputerEquipmentMember

 us-gaap: ComputerEquipmentMember

 TSOI:OfficeFurnitureAndEquipmentMember

 TSOI:OfficeFurnitureAndEquipmentMember

 TSOI:ShippingAndOtherEquipmentMember

 TSOI:ShippingAndOtherEquipmentMember

 TSOI:NotesPayableOneMember

 TSOI:NotesPayableOneMember

 TSOI:NotesPayableTwoMember

 TSOI:NotesPayableTwoMember

 TSOI:NotesPayableThreeMember

 TSOI:NotesPayableThreeMember

 TSOI:NotesPayableFourMember

 TSOI:NotesPayableFourMember

 TSOI:NotesPayableFiveMember

 TSOI:NotesPayableFiveMember

 TSOI:NotesPayableOneMember

 TSOI:NotesPayableOneMember

 TSOI:NotesPayableTwoMember

 TSOI:NotesPayableTwoMember

 TSOI:NotesPayableFourMember

 TSOI:NotesPayableFourMember

 TSOI:NotesPayableFiveMember

 TSOI:NotesPayableFiveMember

 TSOI:OfficersAndDirectorsMember

 TSOI:OfficersAndDirectorsMember

 us-gaap: DerivativeMember

 us-gaap: MeasurementInputExercisePriceMember

 us-gaap: DerivativeMember

 us-gaap: ConvertibleNotesPayableMember

 us-gaap: MeasurementInputExercisePriceMember

 srt: OfficerMember

 2019-12-31

 srt: OfficerMember

 2018-12-31

 TSOI:OneOfficersMember

 TSOI:FourOfficerAndOneDirectorMember

 2022-04-05
 2022-04-05

 TSOI:OneOfficerAndOneDirectorMember

 2022-09-08
 2022-09-08

 TSOI:FourOfficerOneDirectorMember

 2022-11-02
 2022-11-02

 TSOI:FourOfficerAndOneDirectorMember

 2022-12-30
 2022-12-30

 TSOI:OneOfficersMember

 2023-01-09
 2023-01-09

 TSOI:OneDirectorMember

 2023-01-09
 2023-01-09

 TSOI:OneOfficersMember

 2023-04-20
 2023-04-20

 us-gaap: RestrictedStockMember

 2023-05-10
 2023-05-10

 TSOI:OneOfficersMember

 2023-10-16
 2023-10-16

 TSOI:ThreeOfficerAndOneDirectorMember

 2023-10-16
 2023-10-16

 2023-01-03
 2023-01-03

 us-gaap: ConvertibleNotesPayableMember

 2023-01-03
 2023-01-03

 us-gaap: ConvertibleNotesPayableMember

 2022-08-04
 2022-08-04

 2022-08-09

 TSOI:ResNovaBioIncMember

 TSOI:CampbellNeurosciencesIncMember

 2024-04-12
 2024-04-12

 2023-03-22

 2023-03-22
 2023-03-22

 us-gaap: ConvertibleNotesPayableMember

 2024-01-24
 2024-01-24

 2024-02-09
 2024-02-09

 us-gaap: SeriesBPreferredStockMember

 2024-02-09

 2024-02-09

 2024-02-22
 2024-02-22

 2024-03-04
 2024-03-04

 2024-03-04

 2024-03-12
 2024-03-12

 us-gaap: SeriesBPreferredStockMember

 2024-03-18
 2024-03-18

 utr:sqft

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 WASHINGTON,
D.C. 20549

 FORM

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended December 31, 2023

 OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from _____to_____

 Commission
File Number: 000-54554

 Therapeutic
Solutions International, Inc.

 (Exact
name of registrant as specified in its charter)

 Nevada

 45-1226465

 (State
 or other jurisdiction of

 incorporation
 or organization)

 (I.R.S.
 Employer

 Identification
 No.)

 Wild Rose Lane

 Elk
 City, Idaho 83525

 (Address
 of principal executive offices, including zip code)

 (760) 295-7208

 (Registrant's
 telephone number, including area code)

 Securities
 registered pursuant to Section 12(b) of the Act:

 None

 Securities
 registered pursuant to Section 12(g) of the Act:

 Title
 of class

 Common
 Stock, $0.001 par value per share

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 Yes
 No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

 Yes
 No

by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and
will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting
company" in Rule 12b-2 of the Exchange Act.

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

 The
aggregate market value of the voting and non-voting common equity held by non-affiliates was $ 6,581,483 based on a closing price of $0.0021
as of June 30, 2023.

 As
of April 17, 2024, 4,230,116,869 shares of the registrant's common stock, par value of $0.001 per shares, were outstanding.

 PAGE
 NO

 ITEM

 BUSINESS

 ITEM
 1A

 RISK FACTORS

 ITEM
 1B

 CYBERSECURITY

 ITEM

 PROPERTIES

 ITEM

 LEGAL PROCEEDINGS

 ITEM

 MINE SAFETY DISCLOSURES

 ITEM

 MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 ITEM

 SELECTED FINANCIAL DATA

 ITEM

 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 ITEM
 7A

 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 ITEM

 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 ITEM

 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 ITEM
 9A

 CONTROLS AND PROCEDURES

 ITEM
 9B

 OTHER INFORMATION

 ITEM

 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 ITEM

 EXECUTIVE COMPENSATION

 ITEM

 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 ITEM

 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 ITEM

 PRINCIPAL ACCOUNTANT FEES AND SERVICES

 ITEM

 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 SIGNATURES

 PART
I.

 FORWARD-LOOKING
STATEMENTS

 This
Annual Report on Form 10-K contains forward-looking statements within the meaning of federal securities laws, which are subject to a
number of risks and uncertainties. All statements that are not historical facts are forward-looking statements, including statements
about our business strategy, uncertainty regarding our future operating results and our profitability, anticipated sources of funds and
all plans, objectives, expectations and intentions and any statements regarding future potential revenue, gross margins and our prospects
for 2023 and thereafter. These statements may appear in a number of places and can be identified by the use of forward-looking terminology
such as "may," "will," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "future," "intend," or "certain"
or the negative of these terms or other variations or comparable terminology, or by discussions of strategy.

 The
following factors are among those that may cause actual results to differ materially from our forward-looking statements:

 Need
 for additional capital;

 Limited
 operating history in our new business model;

 Limited
 experience introducing new products;

 Our
 ability to successfully expand our operations and manage our future growth;

 Difficulty
 in managing our growth and expansion;

 Dilutive
 effects of any raising of additional capital;

 The
 deterioration of global economic conditions and the decline of consumer confidence and spending;

 Material
 weaknesses reported in our internal control over financial reporting;

 Our
 ability to protect intellectual property rights and the value of our products;

 The
 potential for product liability claims against us;

 Our
 dependence on third party manufacturers to manufacture our products;

 Our
 common stock is currently classified as a penny stock;

 Our
 stock price may experience future volatility;

 The
 illiquidity of our common stock; and

 Substantial
 sales of shares of our common stock.

 Actual
results may vary materially from those in such forward-looking statements as a result of various factors, including those identified
in "Item 1A. Risk Factors" and elsewhere in this document. No assurance can be given that the risk factors described in this
Annual Report on Form 10-K are all of the factors that could cause actual results to vary materially from the forward-looking statements.
Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties, and assumptions. The Company's
future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned
not to put undue reliance on any forward-looking statements. Forward-looking statements also include statements in which words such as
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"consider," or similar expressions are used. References in this Annual Report on Form 10-K to the "Company,"
"TSOI," "we," "our," and "us" refer to Therapeutic Solutions International, Inc.

 ITEM

 BUSINESS.

 Corporate
History

 Therapeutic
Solutions International, Inc. ("TSOI" or the "Company") was organized August 6, 2007, under the name Friendly
Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto
Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.

 On
December 17, 2020, Therapeutic Solutions International, Inc. Board of Directors decided to move our corporate headquarters to Elk City,
Idaho 83525 and has purchased real property at 701 Wild Rose Lane and 50 Bullock Lane, Elk City Idaho 83525. The Company will continue
to maintain a satellite office at the current address of 4093 Oceanside Blvd., Suite B, Oceanside CA, 92056.

 Business
Description

 Currently
the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to
upregulate (make more active) or downregulate (make less active) one's immune system.

 Activating
one's immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections
and to prevent illness. Additionally, inhibiting one's immune system is vital for reducing inflammation, autoimmune disorders,
and allergic reactions.

 TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
and for daily health.

 Nutraceutical
Division – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune, is a multi-patented
synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone. QuadraMune has been shown to increase Natural
Killer Cell activity and healthy Cytokine production.

 Regenerative
Medicine – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

 The
stem cell licensed, termed "JadiCell" is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal
like stromal cells.

 Immunotherapies

 TSOI
has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to Parkinson's disease developed on
our StemVacs platform.

 Investigational
Drug Applications:

 Treatment
of Metastatic Breast Cancer by StemVacs-V Cancer Immunotherapeutic IND transferred to Res Nova Bio, Inc.

 The
Primary Objective is safety and feasibility of StemVacs-V administration at 12 months as assessed by lack of adverse medical events.
The Secondary Objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.

 Safety,
Feasibility, and Immunomodulatory Activities of StemVacs in Patients with Advanced Solid Tumors

 The
Primary Objective is safety and feasibility of StemVacs administration at 12 months as assessed by lack of adverse medical events. The
Secondary Objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.

 ARDScell
Umbilical Cord-derived Mesenchymal Stem Cells for Patients with Acute Respiratory Distress Syndrome

 The
overall objective of this protocol is to confirm safety and determine effectiveness of Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
infusions in subjects with ARDS.

 The
primary objective will be to assess effectiveness of UC-MSC treatment on proportion of patients alive and free of respiratory failure
at Day 60 after randomization.

 The
secondary objectives will be to assess all-cause mortality at Day 60, survival at day 31, number of subjects experiencing serious adverse
events (SAEs) by day 31, SAE-free survival, time to recovery (evaluated until day 60), and time to oxygen requirement equal or below
40% oxygen.

 CTEcell
Investigation of Umbilical Cord-derived Mesenchymal Stem Cells for the Treatment of Chronic Traumatic Encephalopathy Patients transferred
to CTE Biologics, Inc.

 To
determine safety and efficacy of 100 million intravenously administered CTEcell allogeneic umbilical cord mesenchymal stem cells.
Efficacy will be determined by behavioral scores, brain imaging, and reduction in inflammatory markers. Toxicity of treatment was evaluated
for the duration of the study and will be graded according to the criteria of the World Health Organization.

 COPDcell
Therapy IND transferred to Breathe Biologics, Inc.

 To
determine safety and efficacy of intravenously administered allogeneic JadiCell umbilical cord blood mesenchymal stem cells in patients
with moderate-to-severe COPD. The Primary Endpoint, which is toxicity, will be assessed by number of adverse events (AEs). The Secondary
Endpoint, which is efficacy will be evaluated at baseline and days 30, 60, and 90.

 Orphan
Drug Designation:

 Rare
diseases affect patients and their families. Over 7,000 rare diseases affect more than 30 million people in the United States. Many rare
conditions are life threatening, and most do not have treatments.

 The
FDA works to enhance to the availability of treatments for rare diseases by evaluating information from product sponsors to determine
if drugs meet the criteria for certain incentives and administering grants to provide funding for research on rare diseases.

 The
Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet certain criteria. Orphan drug
designation provides incentives including:

 Tax
 credits for qualified clinical trials

 Exemption
 from user fees

 Potential
 for seven years of market exclusivity after approval

 On
June 26, 2023, the Company applied for Orphan Drug Designation Using JadiCell Adult Stem Cells for Treatment of Acute Respiratory Distress
Syndrome.

 On
July 12, 2023, the Company applied for Orphan Drug Designation Using JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia.

 Nutraceutical
Division (TSOI)

 ProJuvenol
 is a patented, (US No.: 9,682,047) and powerful synergistic blend of complex anti-aging ingredients in capsules.

 NanoStilbene
 is an easily absorbed nanoemulsion of nanoparticle pterostilbene derived from the '047 patent.

 DermalStilbene
 is a topical form of pterostilbene delivered via spray application onto skin, derived from the '047 patent.

 IsoStilbene
 an injectable formulation of pterostilbene is available by prescription only, derived from the '047 patent.

 NeuroStilbene
 is an intranasal form of pterostilbene delivered via spray application inside the nostril, derived from the '047 patent.

 NanoPSA
 is a blend of NanoStilbene and Broccoli Sprout Extract (BSE) providing 74mg of BSE and 125mg of our patented NanoStilbene, a
 proprietary formulation of nanoparticle pterostilbene.

 NLRP3
 Trifecta is a two-product combo and consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract.

 QuadraMune
 is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone.

 Patents:

 On
 February 26, 2024, the Company filed a patent application titled " Stem Cell Facilitation of Gene Therapy Induced Differentiation
or Transdifferentiation " that discloses methods, compositions of matter and procedures for enhancing insulin production through
concurrent regenerative and genetic therapy. In one embodiment the invention teaches administration of regenerative cells concurrent
with PDX-1 gene administration. Said regenerative cells include mesenchymal stem cells, hematopoietic stem cells, and tissue specific
progenitor cells. In one specific embodiment endogenous stem cells are mobilized after administration of PDX-1 in order to increase differentiation
of pancreatic progenitors. In one embodiment, coadministration of MDX1 gene together with mesenchymal stem cells is provided to treat
conditions such as multiple sclerosis. Further enhancement of therapeutic activity is mediated through co-administration of T regulatory
cells and/or agents that stimulate T regulatory cells.

 On
 September 29, 2023, the Company filed a patent application titled " Immunological Enhancement of Transplanted Dopaminergic
Cells by Administration of Donor Derived Neutrophil Progenitors " which disclosed compositions of matter, protocols and therapeutic
means to enhance engraftment and viability of pluripotent stem cell derived dopaminergic cells by simultaneously administering donor
derived neutrophils or neutrophil progenitors. In one embodiment said neutrophil progenitors are engineered to express tolerogenic molecules
such as Fas Ligand. In another embodiment pluripotent stem cells are cultured in BMP4 containing media to generate embryoid bodies which
are subsequently dissociated and treated with G-CSF and interleukin 10.

 On
 July 18, 2023, the Company filed a patent application titled " Compositions for Preserving and/or Augmenting T and NK
Cell Immunity in Cancer Patients " which discloses compositions of matter useful for preserving and/or augmenting T and NK cell
immunity through prevention of T cell receptor zeta chain loss. In one embodiment a cancer patient is treated with a combination of pterostilbene
and RU486 at a sufficient concentration and frequency to reduce loss of T cell receptor zeta chain caused by cancer. In one embodiment
said RU486 and pterostilbene combination is administered together with one or more immunotherapeutic agents. In one embodiment said immunotherapeutic
agents are activators of one or more toll like receptors.

 On
 May 01, 2023, the Company filed a patent application titled " Aneurysm Treatment by Exosomes " which provides
means of inhibition and/or treating aneurysms and other degenerated blood vessels through administration of regenerative cell derived
exosomes, and/or regenerative cell derived apoptotic bodies. In one particular embodiment vessel regeneration is increased through administration
of stem cell exosomes/or stem cell apoptotic bodies. Other embodiments include regeneration of vessels prone to aneurysms, repairing
aneurysms of vessels, or acceleration of endothelialization after stent placement. Provided within the invention are methods of rejuvenating
properties of said vessels associated with physiological health, examples of which include appropriate production of anti-coagulating/clotting
factors, control of angiogenesis, and appropriate revascularization of injured tissue.

 On
 March 13, 2023, the Company filed a patent application titled " Generation and Utility of B Cell Subsets for Treatment
of Chronic Obstructive Pulmonary Disease " which disclosed are B cell subsets, generation of B cell subsets and utilization
of B cell subsets for treatment of Chronic Obstructive Pulmonary Disease (COPD). In one embodiment B cells possessing a B regulatory
phenotype are generated in vivo by administrating of mesenchymal stem cells. In another embodiment B regulatory cells are utilized to
treat COPD in an interleukin-35 dependent manner. In another embodiment B regulatory cells possess the marker CD5 and produce interleukin-10.

 On
 February 14, 2023, the Company filed a patent application titled " Enhancement of Anti-Angiogenic Cancer Immunotherapy
by Abortogenic Agents " which discloses the parallels between pregnancy and cancer that have been historically made, however,
the ability to leverage abortogenic immunity against neoplasia has not been widely examined. The current invention provides means of
suppressing tumor associated immune inhibition through administration of progesterone and/or glucocorticoid receptor antagonists such
as RU-486. In one embodiment the invention provides the concurrent utilization RI-486 and anti-angiogenic immunotherapy. In another embodiment,
abortogenic inhibitors of immunity such as indolamine 2,3 dioxygenase are administered together with RU-486 and/or anti-angiogenic immunotherapy.
Various antiangiogenic agents can be utilized in the practice of the invention including the ValloVax immunotherapy and/or the StemVacs-V
therapy.

 On
 January 09, 2023, the Company filed a patent application titled " Prediction of Stem Cell Therapy Responsiveness by Quantification
of Pre-Existing B Regulatory Cells " which disclosed novel means of stratifying patients into potential of positive response
to mesenchymal stem cell therapy based on quantification of pretreatment levels of B regulatory cells. In one embodiment quantification
of cells concurrently expressing CD5 and CD19. In another embodiment B regulatory cells are CD19+CD39–IL10+. In one embodiment
the selection of B regulatory cells is quantified by flow cytometric means and patients possessing more than 7 % IL-10 secreting CD19
cells are chosen for stem cell therapy. In some embodiments numbers of B regulatory cells are increased prior to treatment by administration
of various interventions including providing GM-CSF, microbiome alteration or manipulation of oxidative stress.

 On
 January 04, 2023, the Company filed a patent application titled " Enhanced Efficacy of Tolerogenic Vaccination "
which disclosed means, methods, and compositions of matter useful for induction of antigen specific suppression of immunity and/or tolerogenesis
through administration of tolerogenic agents together with antigens and/or modified antigens delivered via multiple intradermal injections.
In one embodiment the invention teaches the use of a tattoo gun or a similar device to administer over an extended area of skin a compound
which induces a tolerogenic microenvironment and subsequently administration of said antigen in the artificially created microenvironment.
The essence of the disclosed invention is the superior tolerogenic effects observed when tolerogenic stimuli and antigen are administered
over an extended area of skin through the use of a tattoo gun or similar device.

 On
 November 14, 2022, the Company filed a patent titled " Treatment of Chronic Obstructive Pulmonary Disease with Myeloid
Derived Suppressor Cells " which discloses compositions of matter, protocols, and treatment means for prevention and/or reversing
Chronic Obstructive Pulmonary Disease (COPD) using myeloid derived suppressor cells as a monotherapy or adjuvant therapy. In one embodiment
umbilical cord low density myeloid cells are expanded using interleukin-3 and GM-CSF and administered in an allogeneic manner to a mammal
suffering from COPD. In some embodiments combinations of myeloid derived suppressor cells and mesenchymal stem cells are disclosed.

 On
 October 24, 2022, the Company filed a patent application titled " Mesenchymal Stem Cell Therapy of Epilepsy and Seizure
Disorders " which discloses novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through
administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes. In one embodiment umbilical
cord mesenchymal stem cells are administered to a patient suffering from epilepsy at a concentration and frequency sufficient to inhibit
neuronal hyperactivation and/or reduce neuroinflammatory status of the patient.

 On
October 03, 2022, the Company filed a patent application titled " Stimulation of Pulmonary Regenerative Exosomes by Mesenchymal
Stem Cells and Derivatives Thereof " which discloses therapeutic means for pulmonary degenerative conditions through the administration
of mesenchymal stem cells in order to induce regenerative exosomes from dendritic cells expressing CD103. In one embodiment cultures
of mesenchymal stem cells with dendritic cell progenitors are disclosed wherein said mesenchymal stem cells induce a modulation of STAT3
signaling in said dendritic cell endowing a regenerative property to said dendritic cells and exosomes derived from said cells.

 On
 September 19, 2022, the Company filed a patent application titled " Treatment of Bipolar Disorder Using Mesenchymal Stem
Cells and Modification of Mesenchymal Stem Cells " that discloses the utilization of mesenchymal stem cells, exosomes from mesenchymal
stem cells, conditioned media from mesenchymal stem cells, apoptotic bodies from mesenchymal stem cells, and modified mesenchymal stem
cells for treatment of bipolar disorder. In one embodiment mesenchymal stem cells isolated from umbilical cord tissue are treated with
carbon monoxide at a concentration sufficient to induce activation of heme-oxygenase I and infused into a patient at risk or suffering
from bipolar disorder.

 On
 September 12, 2022, the Company filed a patent application titled " Treatment of COPD by Stimulation of Stem Cell Mobilization "
which discloses means of inducing pulmonary regeneration and/or protection from oxidative stress by stimulation of endogenous stem cell
mobilization together with one or more inhibitors of NF-kappa B and/or one or more inhibitors of oxidative stress. The invention discloses
the unexpected finding that G-CSF administration enhances oxidative stress and pulmonary damage, however, coadministration with pterostilbene,
results in synergistic suppression of COPD pathology.

 On
 August 29, 2022, the Company filed a patent application titled " Gene Silencing Therapy of Acute Respiratory Disorder "
that teaches treatment means, compositions of matter and protocols useful for suppression of acute respiratory disorder (ARDS) through
induction of RNA interference in the pulmonary microenvironment alone and/or in conjunction with mucolytic and/or DNA disrupting agents.
In one embodiment short interfering RNA (siRNA) is prepared which targets complement receptors C3R and/or C5R together with TNF-receptor,
IL-6 receptor and/or TLR4 and TLR9. In some embodiments NanoStilbene is utilized as a delivery vehicle for siRNA delivery.

 On
 August 12, 2022, the Company filed a patent application titled " Treatment of Chronic Obstructive Pulmonary Disease by
Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof " that discloses means, treatments and compositions of matter
useful for treatment of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of
mesenchymal stem cell apoptotic bodies alone or in combination with "regenerative adjuvants" to prevent and/or reverse reduction
in lung function associated with COPD. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction
of pulmonary regeneration directly or indirectly.

 On
 July 29, 2022, the Company filed a patent application titled " Gene Modified iPSC Derived Cellular Compositions for Regeneration
and Immune Modulation " that disclosed cells and cellular compositions useful for treatment of degenerative and/or autoimmune
diseases derived from gene edited/gene modified pluripotent stem cells. In one embodiment pluripotent stem cell such as inducible pluripotent
stem cells are gene modified to express tissue associated transcription factors such as pdx-1 if endodermal tissue is desired and cells
are differentiated into regenerative-type cells such as along the mesenchymal lineage. In one embodiment the invention teaches transfection
with IL-27 to induce expression of coinhibitory molecules for suppression of autoimmunity. In some embodiments the invention provides
generation of iPSC derived MSC which cannot stimulate inflammation due to gene-editing based removal of inflammatory associated transcription
factors.

 On
 May 12, 2022, the Company filed a patent application titled " Inhibition and Reversion of Chronic Obstructive Pulmonary
Disease (COPD) by Endothelial Cell Regeneration " that teaches means, treatment methods, and compositions of matter useful for
prevention and/or reversion of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration
of mesenchymal stem cells and exosome thereof as a means of augmenting endogenous endothelial regeneration and/or endothelial regeneration
stimulated by exogenous means. In some embodiments the invention provides administration of allogeneic mesenchymal stem cells together
with autologous endothelial progenitor cells and/or mobilization of said autologous endothelial progenitor cells.

 On
 March 7, 2022, the Company filed a patent application titled " Treatment of Trauma Associated Cognitive Dysfunction Using
Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof " which teaches means, treatments and compositions of matter
useful for treatment of chemotherapy/radiotherapy associated cognitive dysfunction. In one embodiment the invention provides the administration
of mesenchymal stem cell apoptotic bodies alone or in combination with "regenerative adjuvants" to prevent and/or reverse
cognitive dysfunction associated with chemotherapy and/or radiation therapy. In other embodiments the invention teaches the utilization
of stem cell apoptotic bodies for induction of neuroregeneration directly or indirectly.

 On
 February 7, 2022, the Company filed a patent application titled " Treatment of COVID-19 Associated Cognitive Dysfunction
by Nutraceutical Preparations " that teaches means and methods of treating cognitive dysfunction associated with COVID-19 and/or
other associated with inflammatory conditions. In one embodiment treatment of COVID-19 cognitive dysfunction performed by administration
of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation
of endogenous neural progenitor cells and/or protect cells from inflammatory damage. In one embodiment said nutraceuticals are comprised
of green tea extract, and/or nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiments nutraceutical compositions
are utilized to overcome treatment resistant of currently used antidepressants.

 On
 November 1, 2021, the Company filed a patent application titled " Induction of Concurrent Pulmonary Immune Modulation
and Regeneration by Protein Mediated Conjugation of Immune Regulatory Cells with Endogenous Progenitor Cells " that discloses
means, methods and compositions of matter useful for treatment of inflammatory pulmonary diseases such as COVID-19 through administration
of agents that facilitate interaction between immune modulatory cells and endogenous pulmonary progenitor cells. In one embodiment a
bispecific antibody capable of facilitating the interaction between CD25 on T regulatory cells and CD47 on pulmonary epithelial stem
cells is described.

 On
 October 11, 2021, the Company filed a patent application titled " Umbilical Cord Derived Regenerative and Immune Modulatory
Stem Cell Populations " which provides universal donor cellular populations derived from umbilical cords possessing ability
to elicit immune modulation and evoke regeneration when administered into a mammalian host. Generation of cellular products for clinical
use are provided including methodologies of expansion, characterization, and means of therapeutic implementation.

 On
 October 4, 2021, the Company filed a patent application titled " Reduction of Neutrophil Extracellular Trap formation
by Mesenchymal Stem Cells and their Exosomes " that disclosed methods of reducing lung inflammation in acute respiratory distress
syndrome elicited by various factors such as COVID-19 infection by reduction of neutrophil extracellular trap formation through administration
of mesenchymal stem cells and/or exosomes thereof. The invention provides means of inhibiting neutrophil release of extracellular traps
by mesenchymal stem cells and/or exosomes derived from said mesenchymal stem cells. Additionally, synergies are provided between mesenchymal
stem cells and/or exosomes derived from mesenchymal stem cells and agents approaches which reduce neutrophil extracellular trap formation.

 On
 September 22, 2021, the Company filed a patent application titled " Stimulation of Mesenchymal Stem Cell Therapeutic Activities
by T Regulatory Cells " teaches novel means of enhancing mesenchymal stem cell regenerative activities including, intra alia,
production from pulmonary leakage and suppression of scar tissue formation by co-administration with T regulatory cells. In some embodiments
the invention provides an interaction between T regulatory cells and mesenchymal stem cells in which T regulatory cells stimulate upregulation
of mesenchymal stem cell activity in a GITR dependent manner.

 On
 September 16, 2021, the Company filed a patent application titled " Ivermectin Compositions for Treatment of COVID-19 "
that discloses novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic
activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane.
In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive
mechanisms.

 On
 August 23, 2021, the Company filed a patent application titled " Umbilical Cord Mesenchymal Stem Cells for Treatment of
Chronic Obstructive Pulmonary Disease and Lung Degeneration " that discloses means of treating lung degenerative diseases including
chronic obstructive pulmonary disease (CODP) using umbilical cord mesenchymal stem cells such as JadiCells alone, and/or using said cells
under conditions that are activated in order to endow enhanced regenerative activity. In one embodiment said activation of said mesenchymal
stem cells is performed through stimulation with a toll like receptor agonist at a concentration and duration sufficient to induce a
>50% increase in keratinocyte growth factor expression from said stem cells. In another embodiment the invention provides the use
of JadiCells as a means of producing exosomes, wherein said exosomes possess therapeutic properties capable of reducing inflammation,
fibrosis and degeneration associated with COPD, as well as stimulation of regenerative activity. In some JadiCells are activated by a
treatment with Activated Protein C.

 On
 August 18, 2021, the Company filed a patent application titled "E nhancement of Umbilical Cord Mesenchymal Stem Cell Therapeutic
Activity by Stimulators of T Regulatory Cells and/or Cells Expressing CD73 " that teaches compositions of matter and protocols
useful for treatment of COVID-19 and/or other inflammatory pathologies through stimulation of T regulatory cells and/or T cells expressing
CD73 using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment dosage of JadiCells needed
to treat a patient is determined by the increase of T regulatory cells and/or CD73 expressing cells that are increased in number and/or
activity subsequent to a test dose of JadiCells. In another embodiment stimulators of T regulatory cells and/or CD73 expressing T cells
are utilized together with JadiCells in order to augment therapeutic activity. In some embodiments administration of JadiCell is performed
with low dose interleukin-2 as a treatment for COVID-19 or other inflammatory related pathologies.

 On
 August 11, 2021, the Company filed a patent application titled " Induction of Neurogenesis using Umbilical Cord Derived
Mesenchymal Stem Cells and Derivatives Thereof " that disclosed compositions of matter and protocols useful for treatment of
neurological dysfunctions through stimulation of adult neurogenesis using administration of umbilical cord derived mesenchymal stem cells
such as JadiCells. In one embodiment viral induced neuropathy is reduced by administration of JadiCells to stimulate neurogenesis. In
another embodiment the neurogenic activity of selective serotonin reuptake inhibitors is enhanced by administration of JadiCells. In
some embodiments administration of JadiCell exosomes, conditioned media, microvesicles and/or apoptotic bodies is utilized to stimulate
neurogenesis.

 On
 July 28, 2021, the Company filed a patent application titled " Neuroprotection and Neuroregeneration by Pterostilbene
and Compositions Thereof " with new data demonstrating that the blueberry derived compound pterostilbene possesses numerous
brain protective and potentially brain regenerative activities. The data disclosed by the Company indicates: a) pterostilbene suppresses
inflammatory cytokines TNF-alpha, IL-1 beta and IL-6; b) pterostilbene inhibits death of neurons caused by inflammatory mediators; c)
pterostilbene stimulates production of regenerative factors from cells in the brain such as BDNF, NGF, FGF-1, and FGF-2; and d) pterostilbene
allows/enhances proliferation of endogenous brain stem cells.

 Granted
on November 23, 2022.

 On
 July 6, 2021, the Company filed a patent application titled " Treatment of Parkinson's Disease by Immune Modulation
and Regenerative Means " in which we describe and disclose means, methods and compositions of matter for treatment Parkinson's
Disease through concurrent immune modulation and regenerative means. In one embodiment Parkinson's Disease is treated by augmentation
of T regulatory cell numbers and/or activity while concurrently providing regenerative cells such as mesenchymal stem cells, and/or dopamine
secreting cells. In one embodiment administration of immunoglobulins such as IVIG together with low dose interleukin-2 and/or low dose
naltrexone is disclosed as a preparatory means prior to administration of therapeutic cells such as stem cells. Other therapeutic means
utilized in an adjuvant manner are also provided for hormonal rebalancing, transcranial magnetic stimulation, and deep brain stimulation.

 On
 May 24, 2021, the Company filed a patent application titled " Immunotherapies for Targeting of Tumor Vasculature "
that disclosed novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological
memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting
immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine.
In some embodiment's genes are engineered under control of specific promoters to allow for various specificities of activity. In
one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the - Gal epitope
(Gal 1,3Gal 1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means
of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.

 Published
on November 24, 2022.

 On
 May 21, 2021, the Company filed a patent application titled " Lithium as a Monotherapy and/or Stem Cell Adjuvant Therapy
for Pulmonary Fibrosis " that disclosed compositions of matter, therapeutics, and protocols useful for reduction and/or reversion
of pulmonary fibrosis. In one specific embodiment lithium chloride is administered together with a regenerative cell in a patient suffering
from, or at risk of pulmonary fibrosis. In one embodiment said lithium chloride is administered as an adjuvant to a regenerative therapy,
wherein said regenerative therapy is a gene therapy, a protein therapy, a cell therapy, or a tissue transplant. In one embodiment lithium
chloride, or a salt thereof is utilized alone, or with a regenerative means, to evoke preservation and/or elongation of telomere length
in pulmonary tissue. In one embodiment the invention teaches administration of umbilical cord mesenchymal stem cells (MSC) and/or products
derived from said cells in order to induce an inhibition of natural or pathological reduction of telomere length, to preserve telomere
length or to enhance telomere length. In one embodiment the MSC described in the invention as useful are umbilical cord derived MSC.
Published on November 24, 2022.

 On
 May 17, 2021, the Company filed a patent application titled " Treatment of Major Depressive Disorder by Low Dose Interleukin-2 "
which teaches methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration
of low dose interleukin- 2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement
of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard
antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as
a treatment of major depressive disorder.

 On
 April 13, 2021, the Company filed a patent application titled " Amelioration and Treatment of Opioid Addiction "
that discloses compositions of matter, protocols and treatment means for reducing and/or preventing opioid addiction. In one embodiment
the invention teaches intranasal administration of umbilical cord blood plasma, or extracts thereof, together with pterostilbene or pterostilbene
containing nanoparticles, and/or oxytocin, and/or human chorionic gonadotropin.

 On
 March 29, 2021, the Company filed a patent application titled " Compositions Capable of Stimulating Immunity Towards Tumor
Blood Vessels " which discloses novel means, protocols, and compositions of matter for eliciting an immune response against
blood vessels supplying neoplastic tissue. In one embodiment pluripotent stem cells are transfected with one or more genes capable of
eliciting immunity. In some embodiments such genes are engineered under control of specific promoters to allow for various specificities
of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the -Gal
epitope (Gal 1,3Gal 1,4GlcNAc-R).

 On
 March 23, 2021, the Company filed a patent application titled " Chimeric Cells Comprising Dendritic Cells and Endothelial
Cells Resembling Tumor Endothelium" which disclosed are means, methods and compositions of matter useful for induction of immunological
responses towards tumor endothelial cells. In one embodiment the invention teaches fusion of dendritic cells and cells resembling tumor
endothelial cells and administration of such chimeric cells as an immunotherapy for stimulation of tumor endothelial cell destruction.
In other embodiments pluripotent stem cells are utilized to generate dendritic cells, wherein said dendritic cells are fused with pluripotent
stem cell derived endothelial cells created in a manner to resemble tumor endothelial cells.

 On
 March 16, 2021, the Company filed a patent application titled " Pluripotent Stem Cell Derived Dendritic Cells and Engineered
Dendritic Cells for Cancer Immunotherapy " which disclosed are populations of dendritic cells generated from stem cells capable
of inducing immunity towards cancer. In one embodiment said dendritic cells are generated from allogeneic inducible pluripotent stem
cells, for some uses, said pluripotent stem cells are genetically engineered/edited to induce cancer specific immunity and/or resist
immunosuppressive effect of tumor derived microenvironment. In one embodiment pluripotent stem cells are transfected with cancer stem
cell antigens such as BORIS and/or NR2F6.

 On
 March 4, 2021, the Company filed a patent application titled " Therapeutic Monocytes for Prevention of Suicidal Ideation "
that discloses compositions of matter, protocols, and therapeutic means for treatment of suicidal ideations and/or suppression of suicidal
attempts. In one embodiment the invention provides the use of umbilical cord derived monocytes as a means of treatment. In another embodiment,
monocytes are de-differentiated from adult monocytes using reprogramming means to create monocyte capable of producing anti-inflammatory
as well as regenerative properties useful in reducing suicidal ideations and/or attempts. Published on September 8, 2022.

 On
 February 2, 2021, the Company filed a patent application titled " Ex Vivo Generation of Immunocytes Recognizing Brother
Of The Regulator of Imprinted Sites (BORIS) Expressing Cancer Stem Cells " that discusses means, methods and compositions of
matter useful for induction of immunity towards cancer stem cells by providing a dendritic cell, wherein said dendritic cells express
BORIS and/or peptides derived from BORIS, wherein said dendritic cell is cultured in the presence of one or more immunocytes. In one
embodiment said dendritic cells are derived from umbilical cord blood sources and allogeneic to T cells, which are expanded ex vivo and
used for the purposes of immunotherapy. Published on August 25, 2022.

 On
 February 8, 2021, the Company filed a patent application titled " Stimulation of Natural Kill Cell Memory by Administration
of Dendritic Cells " which disclosed means, methods and compositions of matter useful for induction of natural killer cell memory
by administration of dendritic cells and/or exosomes thereof. In one embodiment a mammal suffering from cancer is administered allogeneic
cord blood derived dendritic cells that are not pulsed exogenously. In one embodiment the dendritic cells are stimulated to possess chemotactic
activity towards the tumor by culture of dendritic cell progenitors in hypoxia. Natural killer cell memory is induced, in part, by triggering
of upregulation of cytokines associated with homeostatic expansion such as interleukin 7 and interleukin 15.

 On
 January 26, 2021, the Company filed a patent application titled " Stimulation of Dendritic Cell Activity by Homotaurine
and Analogues Thereof " which discloses means, methods, and compositions of matter useful for enhancement of dendritic cell
activity. In one embodiment the invention provides the use of GABA agonists such as homotaurine for stimulation of dendritic cell activity.
In one embodiment said dendritic cell activity is enhancement of natural killer cell activity and/or of T cell activity. In one embodiment
NK cell activity is ability to induce cytotoxicity in neoplastically transformed cells, whereas T cell activity is either cytokine production
for CD4 cells or cytotoxicity for CD8 cells.

 On
 December 21, 2020, the Company filed a patent application titled " Immunotherapy for Opioid Addiction " which
teaches means, methods and compositions of matter useful for reduction of brain inflammation and prevention of opioid addiction and/or
tolerance. In one embodiment the invention provides utilization of platelet rich plasma (PRP), alone, or admixed with regenerative/anti-inflammatory
adjuvants, for reduction of neural inflammation. In one embodiments PRP is admixed with oxytocin and administered intranasally in a patient
at risk of opioid addiction. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil, and/or pterostilbene
and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed
with regenerative/anti-inflammatory adjuvants.

 On
 December 8, 2020, the Company filed a patent application titled " Treatment of Major Depressive Disorder and Suicidal
Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing Plant-Based Approaches " that teaches means and methods
of treating major depressive disorder and/or other disorders that predispose to suicide by administration of nutraceutical means, wherein
said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor
cells. In one embodiment said nutraceuticals are comprised of green tea extract, and/or nigella sativa, and/or pterostilbene, and/or
sulforaphane. In some embodiment's nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.

 On
 November 24, 2020, the Company filed a patent application titled " Stimulation of NK Cell Activity by QuadraMune Alone
and together with Metformin " that disclosed means, compounds, and compositions of matter useful for stimulation of natural
killer cell activity. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising
of metformin, pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer
cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected
with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters
observed in patients with COVID-19.

 On
 October 27, 2020, the Company filed a patent application titled " Protection/Regeneration of Neurological Function by
Endothelial Protection/Rejuvenation " using Stem Cells for Treatment of Conditions such as Chronic Traumatic Encephalopathy
and Schizophrenia" which therapeutic compounds, protocols, and compositions of matter useful for treatment of neurological conditions.
In one embodiment the invention teaches the treatment of chronic traumatic encephalopathy (CTE) through protecting/regenerating the endothelial
by administration of cells such as stem cells. In one embodiment stem cells are administered in order to protect the endothelium from
apoptosis and to preserve the blood brain barrier. In another embodiment stem cells are administered together with endothelial progenitor
cells in order to regenerate neural endothelium. In other embodiments preservation of brain integrity in conditions of degeneration is
accomplished by administration of stem cells and/or endothelial cells.

 On
 October 18, 2020, the Company filed a patent application titled " Nutraceutical Reduction Prevention and/or Reversion
of Multiple Sclerosis " that discloses compositions of matter, protocols, and treatment means for preventing and/or reversing
multiple sclerosis in a mammal. In one embodiment administration of compositions containing pterostilbene, and/or nigella sativa, and/or
sulforaphane, and/or epigallocatechin-3-gallate (EGCG) are provided.

 On
 September 24, 2020, the Company filed a patent application titled " Personalized Immunotherapies for Reduction of Brain
Inflammation and Suicide Prevention " that discloses means, methods and compositions of matter useful for reduction of brain
inflammation and prevention of suicidal ideations and suicidal attempts. In one embodiment the invention provides utilization of autologous
platelet rich plasma, alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiment
autologous PRP is admixed with oxytocin and administered intranasally in a patient at risk of suicidal ideation. In another embodiment,
PRP is admixed with fortified and non-fortified nigella sativa oil and administered intranasally. Other embodiments include utilization
of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants.

 On
 September 14, 2020, the Company filed a patent application titled " Immunotherapy of Schizophrenia and Schizophrenia Associated
Suicidal Ideation/Suicide " Disclosed are methods, means, and protocols of modifying the immune system so as to induce an immunologically
tolerant state insofar as T regulatory cell number and/or activity is augmented in a patient suffering from schizophrenia. In one embodiment
T regulatory cells are administered to the patient from exogenous sources, be they allogeneic or autologous. In other embodiments, T
regulatory cells are generated endogenously through administration of immature dendritic cells, mesenchymal stem cells, and/or pharmaceutical
means.

 On
 August 28, 2020, the Company filed a patent application titled " Upregulation of Therapeutic T Regulatory Cells and Suppression
of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline "
which discloses compositions of matter, treatments and protocols useful for induction of T regulatory cells in response to inflammation,
as well as inhibition of suicidal ideations and/or neuroinflammation. In some embodiments the invention teaches the administration of
a therapeutic combination of ingredients comprising of minocycline, pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate
(EGCG) to a mammal undergoing upregulation of inflammatory mediators.

 On
 August 21, 2020, the Company filed a patent application titled " Methods of Determining Risk of Suicide and/or Suicidal
Ideation by Immunological Assessment " which discloses means and methods of identifying risk of suicide and/or suicidal ideation
by assessment of immunologically related cytokines and cells. In one embodiment, a score, termed the "Campbell Score" is
devised based on assessment of serum cytokines, ability of immune cells to make cytokines when stimulated ex vivo, and ability of immune
cells to produce neurotransmitters when stimulated ex-vivo. In one embodiment the concentration of interleukin-6 is utilized as a means
of assessing suicidal propensity along, and/or in combination with metabolites of the enzyme indolamine 2,3 deoxygenase.

 On
 August 05, 2020, the Company filed a patent application titled " Prevention of Neuroinflammation associated Memory Loss
Using Nutraceutical Compositions " which discloses means, methods, and therapeutic compositions for prevention of memory loss
during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients
comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal suffering from inflammation
in order to preserver memory function.

 On
 July 22, 2020, the Company filed a patent application titled " Additive and/or Synergistic Combinations of Metformin with
Nutraceuticals for the Prevention, Inhibition and Treatment of SARS-Cov-2 and Associated COVID-19 " showing potent synergy between
QuadraMune and the antidiabetic drug metformin in treating COVID-19 associated lung damage models. It was discovered that the
ability of QuadraMune to protect the lungs from inflammation that resembles coronavirus-induced pathology is markedly amplified
by concurrent administration of metformin. At a mechanistic level, it was shown that metformin increased the ability of QuadraMune
to a) increase the number of "healing macrophages" ("M2" macrophages); b) augment production of anti-inflammatory
and regenerative proteins; and c) suppress production of pathological inflammatory proteins.

 On
 July 13, 2020, the Company filed a patent application titled " Prevention of Pathological Coagulation in COVID-19 and
other Inflammatory Conditions " s directed to the utilization of pterostilbene, and/or nigella sativa extract, and/or sulforaphane,
and/or Epigallocatechin gallate (EGCG) alone or in combination, for the prevention of pathological coagulation. In on embodiment a composition
containing all four ingredients is administered to a patient at risk of hypercoagulation in order to prevent aberrant expression of pro-coagulation
molecules and/or induce expression of molecules known to suppress coagulation. In one embodiment the invention teaches administration
of pterostilbene, thymoquinone, sulforaphane, and EGCG as a means of decreasing expression of tissue factor.

 On
 June 30, 2020, the Company filed a patent application titled " Augmentation of Natural Killer Cell Activity and Induction
of Cytotoxic Immunity Using Leukocyte Lysate Activated Allogeneic Dendritic Cells: StemVacs " which describes the process
of preparing allogeneic dendritic cells utilizing a leukocyte lysate based approach. These data support development of StemVacs for conditions
that would benefit from NK activation such as cancer and COVID-19.

 On
 June 22, 2020, the Company filed a patent application titled " Treatment of SARS-CoV-2 with Dendritic Cells for Innate
and/or Adaptive Immunity " that disclosed means, methods, and compositions of matter for prophylaxis and/or treatment of SARS-CoV-2
by administration of dendritic cells in a manner and frequency sufficient to induce activation of innate and/or adaptive immune responses.
In one embodiment the invention teaches administration of dendritic cells pulsed with one or more innate immune stimulants in a manner
endowing said dendritic cell with ability to induce augmentation of natural killer (NK) cell number and/or activity. In another embodiment
the invention teaches the use of dendritic cells stimulated with innate immune activators in a manner to allow for uptake of viral particles
and presentation of viral epitopes to T cells in order to stimulate immunological activation and/or memory responses.

 On
 June 15, 2020, the Company filed a patent application titled " Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase "
from new data showing QuadraMune significantly inhibited inflammation associated with memory impairment, as well as reduced levels
of kynurenine. Elevation of kynurenine is associated with activation of indolamine 2,3 deoxygenase, an enzyme associated with inflammation
and depression.

 On
 June 11, 2020, the Company filed a patent application titled " Nutraceuticals for Reducing Myeloid Suppressor Cells "
which disclosed compositions of matter, treatments and protocols useful for reduction of number and/or activity of myeloid suppressor
cells (MSC). In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene,
Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal at possessing an increased number and/or activity of
said MSC in which reduction of number and/or activity is desired. In another embodiment, the invention teaches administration of said
therapeutic combination to a mammal infected with viral and/or bacterial infections and/or neoplasia. In some embodiments dosage of said
therapeutic combination is based on inflammatory and/or immunological parameters observed in patients.

 On
 May 11, 2020, the Company filed a patent application titled " Treatment of COVID-19 Lung Injury Using Umbilical Cord Plasma
Based Compositions " which disclosed means, methods, and compositions of matter useful for the treatment of lung inflammation
associated with viral and bacterial infections, as well as with systemic inflammation, through the administration of umbilical cord blood
derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with
pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized
manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered
with immune-stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.

 On
 May 4, 2020, the Company filed a patent application titled " Nutraceuticals for the Prevention, Inhibition and Treatment
of SARS-Cov-2 and Associated COVID-19 " which teaches compositions of matter, treatments and protocols useful for prevention
of SARS-CoV-2 infection, as well as inhibition of viral propagation and acceleration of viral cure. In some embodiments the invention
teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene, nigella sativa, sulforaphane, and
epigallocatechin-3-gallate (EGCG) to a mammal at risk of infection with SARS-CoV-2. In another embodiment, the invention teaches administration
of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination
is based on inflammatory and/or immunological parameters observed in patients with COVID-19.

 On
 November 4, 2019, the Company filed a patent application titled " Cellular, Organ, and Whole-Body Rejuvenation Utilizing
Cord Blood Plasma and Pterostilbene " that disclosed methods, means, and protocols for stimulation of rejuvenation in single
cells, organs, and organisms by administration of cord blood derived plasma, cord blood plasma concentrates, and cord blood derived exosomes
together with pterostilbene. The invention describes the previously unexpected finding that addition of pterostilbene to cord blood enhances
the rejuvenation properties of cord blood. Said rejuvenation properties include telomere preservation, reduction in beta galactosidase,
and retention of cellular activities.

 On
 September 9, 2019, the Company filed a patent application titled " Pterostilbene and Formulations Thereof for Protection
of Hematopoiesis from Chemotherapy and Radiation " which disclosed compositions of matter useful for treatment and/or prevention
of hematopoietic injury using pterostilbene and formulations thereof. In one embodiment nanoparticle delivered pterostilbene is administered
subsequent to chemotherapy induced neutropenia in order to accelerate recovery of the hematopoietic compartment. In another embodiment,
pterostilbene is provided concurrently with chemotherapy in order to concurrently assist the neoplasia killing action of the chemotherapy
while protecting the bone marrow from suppression. In contrast to conventionally used agents that protect from neutropenia such as G-CSF
and GM-CSF, the products disclosed can be chronically administered, thus allowing for concurrent use with chemotherapeutic or radiotherapeutic
agents.

 On
 January 21, 2019, the Company filed a patent application titled " Prevention and Reversion of Chronic Traumatic Encephalopathy
through Administration of "Educated" Monocytes and Progenitors Thereof " that provides means of preventing and/or
reversing chronic traumatic encephalopathy in a patient through the modulation of monocytes as well as monocytic progenitors. In one
embodiment the invention teaches administration of monocytes that have been previously "educated" by exposure to mesenchymal
stem cells in order to endow onto said monocytes properties associated with stimulation of neuroregenerative properties. In some embodiments
monocytes are educated by treatment of monocytic progenitors with conditions capable of endowing anti-inflammatory and regenerative conditions,
said conditions include culture with epigenetic modifying agents. In other embodiments, the invention teaches the manipulation of cord
blood derived monocytes as a starting population of cells for education by culture with mesenchymal stem cells.

 On
 January 21, 2019, the Company filed a patent application titled " Autologous Neurogenic Cells and Uses Thereof for Professional
Athletes at Risk of Chronic Traumatic Encephalopathy" which disclosed are means, compositions of matter and methods of business
for treating Chronic Traumatic Encephalopathy (CTE) using autologous primary cells and modified cells of autologous origin which have
been banked. In one embodiment of the invention autologous dedifferentiation cells are generated and stored for future administration
in patients which have suffered CTE. In other embodiments, dedifferentiated cells are differentiated into neurons or neuronal progenitor
cells and subsequently administered locally or systemically or in a combination. In other embodiments autologous cells are maintained
in an undifferentiated manner and/or neurologically differentiated state and utilized as a conditioning source in an extracorporeal circulatory
system replicating clinical stage extracorporeal liver perfusion (ECLP) with substitution of autologous
dedifferentiated, neurologically differentiated or a combination of said cells instead of hepatic cells.

 On
 December 18, 2018, the Company filed a patent application titled " Treatment of Chronic Traumatic Encephalopathy via RNA
Administration" which disclosed are protocols, treatment means, and compositions of matter useful for treatment of Chronic
Traumatic Encephalopathy through administration of RNA or modified RNA molecules. In one embodiment said RNA is generated to activate
various toll like receptors (TLR), of which said activation leads to production of cytokines which paradoxically lead to protection from
Chronic Traumatic Encephalopathy, wherein said protection constitutes a) reduction in glial cell activation, b) neuronal apoptosis due
to excitotoxicity; and c) stimulation of endogenous regenerative processes including endothelial progenitor cell mobilization, proliferation
of neuronal progenitor cells in the dentate gyrus and subventricular zones. In one particular embodiment targeting of RNA molecules is
performed to specific brain cells including pyramidal neurons through the use of liposomes, exosomes, apoptotic bodies, nanoparticles
and shark or cameloid antibodies is disclosed.

 On
 September 25, 2018, the Company filed a patent application titled " Pterostilbene and Formulations Thereof for Treatment
of Pathological Immune Activation " that teaches treatments, protocols, and compositions of matter are described for reduction
of pathological immune system activation. In one embodiment, pterostilbene and/or formulations thereof are administered in a patient
suffering from cytokine release syndrome at a concentration and frequency sufficient to reduce abnormal cytokine production and thus
treat the cause of said cytokine release syndrome. Formulations of pterostilbene are disclosed for rapid release, enhanced biodistribution,
and targeting to cytokine releasing effectors are disclosed for use in the practice of the invention.

 On
 September 17, 2018, the Company filed a patent application titled " Pterostilbene and Compositions Thereof for Prevention
and Treatment of Chronic Traumatic Encephalopathy " that teaches means, methods, and compositions of matter useful for prevention
of chronic traumatic encephalopathy. In one embodiment of the invention, disclosed is utilization of pterostilbene and/or pterostilbene
based compounds for prevention and/or treatment of chronic traumatic encephalopathy. In one embodiment, the invention teaches administration
of pterostilbene and/or pterostilbene based compounds for reduction of taupathy associated with chronic traumatic encephalopathy.

 On
 August 13, 2018, the Company filed a patent application titled " Enhancement of Ozone Therapy using Pterostilbene "
that disclosed methods, means and compositions of matter using pterostilbene for enhancing therapeutic efficacy of ozone therapy in the
field of oncology. The invention provides previously unknown synergies between ozone administration together with pterostilbene at inducing
direct and indirect cytotoxicity to cancer cells. The invention provides means of delivery, administration, and therapeutic protocols
for treatment of cancer patients. In one embodiment combination of ozone therapy together with pterostilbene is utilized to overcome
drug resistance.

 On
 October 08, 2017, the Company filed a patent application titled " Synergistic Inhibition of Glioma Using Pterostilbene
and Analogues Thereof " that teaches methods, means and compositions of matter for utilizing pterostilbene and analogues thereof
for suppression of viability, metastasis and proliferation of glioma cells alone, or together with immunotherapy, chemotherapy, or radiotherapy
means. In one embodiment said pterostilbene augments immunogenicity of glioblastoma cells so as to enhance killing by immune cells or
complement subsequent to damage of said glioblastoma cells by chemotherapy, radiotherapy, or immunotherapy.

 On
 April 26, 2017, the Company filed a patent application titled " Augmentation of Stem Cell Activity using Pterostilbene
and Compositions Containing Pterostilbene " that disclosed means of augmenting circulating endogenous stem cells through administration
of an effective amount of pterostilbene or derivatives thereof. In one embodiment a patient with reduced levels of circulating endothelial
progenitor cells is treated with pterostilbene at a concentration and frequency sufficient to restore, and/or enhance levels of circulating
endothelial progenitor cells (EPC). In another embodiment endogenous levels of stem cells are restored or enhanced by administration
of pterostilbene, said endogenous stem cells comprising cells of the dentate gyrus, subventricular zone, hepatic stem cells, cardiac
stem cells, and hematopoietic stem cells.

 On
 March 29, 2017, the Company filed a patent application titled " Stimulation of Immunity to Tumor Stem Cell Specific Proteins
by Peptide Immunization " that discloses treatment of cancer is disclosed through administration of proteins or specific peptides
found on tumor stem cells in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated
proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through
induction of anticancer immunity and/or immunity towards tumor initiating stem cells.

 On
 March 29, 2017, the Company filed a patent application titled " Targeting the Tumor Microenvironment through Nutraceutical
Based Immunoadjuvants " that disclosed compositions useful for the treatment of cancer which modulate tumor associated immunosuppression,
thus acting as immunoadjuvants. In one embodiment a composition containing apigenin, is provided, said composition useful for inhibition
of tumor associated immune suppression mediated through the molecule indolamine 2,3 deoxygenase (IDO). In another embodiment, liposomal
apigenin is administered as a means of decreasing IDO expression.

 On
 March 29, 2017, the Company filed a patent application titled " Activated Leukocyte Extract for Repair of Innate Immunity
in Cancer Patients " that disclosed are compositions, methods of use, and pharmaceutical preparations useful for modulation
of immune responses. In one embodiment a composition is extracted polyvalently activated peripheral blood mononuclear cells through dialysis.
Said immune modulator is useful for treatment of cancer and alleviation of cancer associated immune depression. In one embodiment, said
immunomodulator acts as a costimulatory of T cell activation by modulation of cytokine production. In one embodiment said immune modulator
is concentrated for miRNA species capable of activating innate immune cells.

 On
 March 29, 2017, the Company filed a patent application titled " Augmentation of Anti-Tumor Immunity by Mifepristone and
Analogues Thereof " which relates to compositions of matter and methods useful for improving a treatment outcome and/or an alteration
of immunity in a condition that benefits from immune stimulation. In particular, one embodiment of the invention teaches administration
of sufficient doses of mifepristone or a derivative, alone, or in combination with an immunotherapeutic such as, but not limited to,
an antibody, a vaccine, a cytokine, or a medicament whose therapeutic activity is associated with immune modulation.

 On
 March 29, 2017, the Company filed a patent application titled " Methods of Re-Activating Dormant Memory Cells with Anticancer
Activity " that disclosed methods, protocols, and compositions of matter useful for stimulation of anticancer immune responses.
In one embodiment of the invention culture of buffy coat cells is performed in an environment resembling non-physiological conditions.
Buffy coat derived products are subsequently harvested, concentrated, and added to a culture of monocytes and lymphocytes. Conditioned
media from said second culture is subsequently utilized as an injectable solution for stimulation of anticancer immunity.

 On
 March 29, 2017, the Company filed a patent application titled " Modulation of Oral Microbiome for Treatment of Periodontitis "
that disclosed methods, means, and compositions of matter useful for inhibition of, reduction in progression and reversion of periodontitis.
In one embodiment the invention provides prebiotic and/or probiotic compositions which modulation the oral microbiome in order to ameliorate,
prevent or reverse periodontitis. In one embodiment a composition is administered into the oral cavity containing Actinomyces naeslundii,
Actinomyces odontolyticus, Streptococcus thermophilius, Lactobaccilus brevis and Lactobacilius plantarum. Administration may be performed
using various means including a mouthwash, a patch, a toothpaste, or in a preferred embodiment said prebiotic and/or probiotic compositions
are delivered via a mouth tray.

 On
 July 20, 2016, the Company filed a patent application titled " Prevention of Pregnancy Complications by Probiotic Administration "
which disclosed methods, protocols and compositions of matter for the treatment of pregnancy complications through immune modulation
of a mammal in need. In one embodiment the invention provides probiotic compositions for immune modulation to decrease risk of pregnancy
complications. Pregnancy complications include recurrent spontaneous abortions (RSA), preterm birth, pre-eclampsia including hemolysis
elevated liver enzymes low platelets (HELP), premature rupture of the membrane, Antepartum hemorrhage including placental abruption,
chorioamnionitis, Intrauterine growth restriction, placenta pravaevia, sequalae of intraamniotic infection. Published on January 26,
2017.

 On
 July 20, 2016, the Company filed a patent application titled " Exosome Mediated Innate and Adaptive Immune Stimulation
for Treatment of Cancer " that teaches means of stimulating innate and/or adaptive immunity to cancer by administration of exosomes.
Stimulation of innate immunity involves modifying exosomes by chemical addition of innate immune stimulators, whereas stimulation of
adaptive immunity involves pulsing dendritic cells generating exosomes with antigens, in some cases, pulsing with Brother of the Regulator
of Imprinted Sites (BORIS) proteins, peptides, or altered peptide ligands thereof.

 On
 July 8, 2015, the Company filed a patent application titled " Augmentation of Oncology Immunotherapies by Pterostilbene
Containing Compositions " that disclosed compositions of matter and methods useful to augmentation of immune responses to tumors.
In one embodiment, a pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency
to induce de-repression of tumor targeting immune responses. In one specific embodiment of the present invention, pterostilbene enhances
antibody dependent cellular toxicity (ADCC) and in turn augments efficacy of FDA approved antigen specific immunotherapeutics such as
trastuzumab (Herceptin) and other monoclonal antibody therapies used for treating cancer.

 Issued
and Granted Patents:

 On
 June 20, 2017, the US Patent and Trademark Office issued and granted U.S. Patent No.: 9,682,047 titled " Augmentation
of oncology immunotherapies by pterostilbene containing compositions " that discloses compositions and methods useful to enhancing,
improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer
patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances
antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other
monoclonal antibody therapies useful for treating cancer.

 See:

 On
 January 25, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,229,674 titled " Nutraceuticals
for suppressing indolamine 2,3 deoxygenase " which disclosed are compositions of matter, treatments and protocols useful for
reduction of expression and/or activity of indolamine 2,3 deoxygenase (IDO). In some embodiments the invention teaches the administration
of a therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate
(EGCG) to a mammal at possessing an increased expression and/or activity of said IDO in which reduction of number and/or activity is
desired. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with viral
and/or bacterial infections and/or neoplasia. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or
immunological parameters observed in patients.

 On
 March 08, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,266,707 titled " Nutraceuticals
for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19 " that disclosed methods of treating or
preventing complications associated with a SARS-CoV-2 infection, comprising: administration of a combination comprising: a) Green Tea
and/or extract thereof; b) Blueberry and/or extract thereof; c) Nigella sativa and/or extract thereof; and d) broccoli and/or extract
thereof in an amount and frequency sufficient to treat or prevent complications associated with said SARS-CoV-2 infection.

 On
 November 23, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,504,410 titled " Neuroprotection
and Neuroregeneration by Pterostilbene and Compositions Thereof " with new data demonstrating that the blueberry derived compound
pterostilbene possesses numerous brain protective and potentially brain regenerative activities. The data disclosed by the Company indicates:
a) pterostilbene suppresses inflammatory cytokines TNF-alpha, IL-1 beta and IL-6; b) pterostilbene inhibits death of neurons caused by
inflammatory mediators; c) pterostilbene stimulates production of regenerative factors from cells in the brain such as BDNF, NGF, FGF-1,
and FGF-2; and d) pterostilbene allows/enhances proliferation of endogenous brain stem cells.

 On
 September 19, 2023, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,759,495 titled " Upregulation
of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical
Compositions Alone or Combined with Minocycline " which discloses compositions of matter, treatments and protocols useful for
induction of T regulatory cells in response to inflammation, as well as inhibition of suicidal ideations and/or neuroinflammation. In
some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of minocycline, pterostilbene,
nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal undergoing upregulation of inflammatory mediators.

 *The
data provided here is partial and does not contain all materials submitted for publication and is preliminary until peer review is complete.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure,
or prevent any disease.

 Aneurysm
Treatment by Exosomes

 On
May 1, 2023, the Company announced launching VasoSome Vascular Inc., based on successful treatment of Aortic Aneurysms using patent pending
exosome therapy.

 At
present there is no treatment available for AAA other than open surgical or endovascular repair, both of which carry significant risks.
The Company is currently at an early stage of development but seeks to be first-in-man clinical trials.

 Abdominal
Aortic Aneurysms

 An
AAA is a localized dilation or "ballooning" of the abdominal aorta. Prevalence approaches 5% in men over 60 years and increases
with age. About 7.5% of men over 65 years are affected. Aneurysm disease currently affects about 1.7m individuals in the United States.
The prevalence is expected to exceed 3m by 2025 with the "baby boomers" reaching their seventh decade.

 The
natural history of AAA is progressive growth, leading to rupture and death. The growth rate is about 0.3cm per year and the rate of growth
accelerates as the aneurysm gets bigger. Most AAA's are asymptomatic and remain undetected. until they rupture.

 More
than 80% of patients who suffer a ruptured AAA don't survive long enough to reach a hospital and 50-70% of those who do reach a
hospital don't survive treatment. The likelihood of rupture increases dramatically as the AAA grows. At 5.5cm, the one year incidence
of rupture is about 9%, rising to 33% as the aneurysm grows to 7cm. Ruptured AAA's are a leading cause of death in the USA, and
are the 10 th leading cause of death for men over 55 years. In the US, 1-2% of all male deaths in the over 65 years cohort
are due to AAA. Only 10% of patients with AAA are still alive 8 years after diagnosis compared to 65% of a similar normal population.
Those who die lose an average of nine years of life.

 Technology

 VasoSome's
product VSX-001 is a proprietary nanoparticle derived from specialized stem cells that can be utilized in a "universal donor"
manner, meaning it does not have to be matched with the donor. The product possesses numerous properties of stem cells, including inhibition
of inflammation, suppression of damage to blood vessels, and ability to regenerate damaged tissue. Advantages of administering VSX-001
compared to stem cells include: a) VSX-001 is substantially smaller in size than stem cells, allowing for superior distribution; b) VSX-001
does not multiply, thus possessing a superior long-term safety profile; and c) VSX-001 can be manufactured more economically as compared
to stem cells.

 Acute
Respiratory Distress Syndrome (ARDS)

 On
April 20, 2023, the Company filed with the USFDA an Investigational Drug Application (IND) to initiate a Phase III Clinical Trial for
Acute Respiratory Distress Syndrome.

 ARDS
is a condition in which lung injury causes fluid to leak into the spaces between the capillaries and the alveoli. Pressure on the alveoli
increases, and eventually fluid accumulates. Fluid in the lungs causes the alveoli to collapse, leading to a series of cascading problems,
each further decreasing the lungs' capacity to move oxygen into the blood, and directly impacting the body's tissues and
organs. ARDS afflicts approximately 198,000 Americans a year and is expected to reach a 19.5 billion dollar a year market by 2029.

 Chronic
Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI)

 On
December 10, 2018, Therapeutic Solutions International, Inc., announced the signing of an agreement between TSOI and Jadi Cell LLC for
licensing of the Jadi Cell universal donor adult stem cell, as covered in US Patent No.: 9,803,176 B2 for use in Chronic Traumatic Encephalopathy
(CTE), and Traumatic Brain Injury (TBI).

 On
December 17, 2020, the Company filed an Investigational New Drug (IND) application seeking permission from the Food and Drug Administration
(FDA) to initiate a Phase I/II clinical trial assessing safety and signals of efficacy for treatment of Chronic Traumatic Encephalopathy
(CTE) patients with JadiCells.

 On
May 25, 2023, the Company announced the creation of CTE Biologics, Inc. as a subsidiary company dedicated to commercializing the JadiCell
adult stem cell platform for treatment of chronic traumatic encephalopathy.

 On
July 05, 2023, the Company signed license agreements with CTE Biologics for the exclusive use of US Patent Publication No.: 20220125852
titled as: "Protection and Regeneration of Neurological Function by Using Stem Cells" as well as the sale and transfer of
Investigational New Drug Application titled as: Investigation of Umbilical Cord derived Mesenchymal Stem Cells for the Treatment of Chronic
Traumatic Encephalopathy Patients.

 Chronic
Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and
is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression,
depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal
cortices, and medial temporal lobe.

 Traumatic
brain injury (TBI) is an insult to the brain, not of a degenerative or congenital nature, but caused by external physical force that
may produce a diminished or altered state of consciousness, which results in an impairment of cognitive abilities or physical functioning.

 CTE
represents a significant unmet medical need which we believe is amenable to stem cell intervention. We are eager to accelerate treatments
and potential cures for debilitating conditions such as CTE and traumatic brain injury and plan to leverage New regulatory pathways such
as the recently approved "Right to Try" Law to deliver these medicines as soon as possible to patients which currently have
no other options.

 Schizophrenia/Suicide
Clinical Programs

 On
October 29, 2020, the Company announced publication on the NIH clinical trials website of its newly initiated trial aiming to validate
a blood-based diagnostic for predicting suicide risk and is listed as NCT04606875.

 The
Campbell Score, which is a patent-pending method of quantifying inflammatory-associated biological markers, has previously been
shown in pilot investigator-initiated studies to correlate with propensity for suicide. Based on positive feedback from collaborators,
the Company decided to initiate a formal clinical trial to validate correlations between the Campbell Score and established psychiatric
assessment tools of suicidal propensity. Currently the only means of quantifying predisposition to suicide is based on psychological,
question-based techniques.

 On
December 31, 2020, the Company signed license agreements with Campbell Neurosciences Inc., a partially owned company, for access to the
11 patents filed related to the previous Campbell Neurosciences Division. The patents are:

 No.: 63/128759 Immunotherapy for Opioid Addiction

 No.: 63/122862 Treatment of Major Depressive Disorder and Suicidal Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing
 Plant-Based Approaches

 No.: 63/105964 Protection/Regeneration of Neurological Function by Endothelial Protection/Rejuvenation using Stem Cells for Treatment
 of Conditions such as Chronic Traumatic Encephalopathy and Schizophrenia

 No.: 17/030416 Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention

 No.: 63/077723 Immunotherapy of Schizophrenia and Schizophrenia Associated Suicidal Ideation/Suicide

 No.: 63/071381 Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by
 Administration of Nutraceutical Compositions Alone or Combined with Minocycline

 No.: 63/068388 Methods of Determining Risk of Suicide and/or Suicidal Ideation by Immunological Assessment

 No.: 63/061202 Prevention of Neuroinflammation associated Memory Loss Using Nutraceutical Compositions

 No.: 63/057315 Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof

 Serial No. 63/174291 filed by Licensor and titled as: Amelioration and Treatment of Opioid Addiction.

 Patent
 Application Serial No. 63/189630 filed by Licensor and titled as: Treatment of Major Depressive Disorder by Low Dose Interleukin-2.

 Additionally,
Campbell Neurosciences Inc. has entered into purchase agreements with Therapeutic Solutions International ensuring a continued supply,
at a discounted rate, of nutraceuticals which are being explored for antiinflammation/suicide prevention activity.

 Treatment
of Chronic Obstructive Pulmonary Disease (COPD) Using COPDcell Universal Donor Adult Stem Cells

 On
October 7, 2022, the Company formed Breathe Biologics, Inc. and licensed to them a patent application titled "Umbilical Cord Mesenchymal
Stem Cells for Treatment of Chronic Obstructive Pulmonary Disease and Lung Degeneration" that discloses means of treating lung
degenerative diseases including chronic obstructive pulmonary disease (CODP) using umbilical cord mesenchymal stem cells such as COPDcell's.

 In
addition, the Company has transferred ownership of the filed investigational drug application titled "JadiCell Therapy for COPD"
to determine safety and efficacy of intravenously administered allogeneic JadiCell umbilical cord blood mesenchymal stem cells in patients
with moderate-to-severe COPD. The Primary Endpoint, which is toxicity, will be assessed by number of adverse events (AEs). The Secondary
Endpoint, which is efficacy will be evaluated at baseline and days 30, 60, and 90.

 COPD
is a consistently progressive, ultimately fatal disease for which no treatment exists capable of either reversing or even interrupting
its course. It afflicts more than 5% of the population in many countries, and it accordingly represents the third most frequent cause
of death in the U.S., where it accounts for more than 600 billion in health care costs, morbidity, and mortality.

 COPD
possesses several features making it ideal for stem cell-based interventions: a) the quality of life and lack of progress demands the
ethical exploration of novel approaches. For example, bone marrow stem cells have been used in over a thousand cardiac patients with
some indication of efficacy. Adipose-based stem cell therapies have been successfully used in thousands of race-horses and companion
animals without adverse effects, as well as numerous clinical trials are ongoing and published human data reports no adverse effects.

 Mesenchymal
Stem Cells (MSCs) are potent immunomodulatory cells that recognize sites of injury, limit effector T cell reactions, and stimulate regulatory
cell populations ( i.e., T-regs) via growth factors, cytokines, and other mediators. Simultaneously, MSCs also stimulate local
tissue regeneration via paracrine effects inducing angiogenic, anti-fibrotic and remodeling responses. Consequently, MSCs-based therapy
represents a viable treatment option for autoimmune conditions and other inflammatory disorders, yielding beneficial effects in models
of autoimmune Type 1 Diabetes, Systemic Lupus Erythematosus, Autoimmune Encephalomyelitis, Multiple Sclerosis, cardiac insufficiency,
and organ transplantation. MSCs have been reported to inhibit inflammation and fibrosis in the lungs, have shown safety in clinical trials
for ARDS, and have been recently suggested as useful to treat patients with severe COVID-19 based on their effects preventing or attenuating
the immunopathogenic cytokine storm.

 Unfortunately,
evaluation of stem cell therapy in COPD has lagged behind other areas of regenerative investigation; b) the underlying cause of COPD
appears to be inflammatory and/or immunologically mediated. The destruction of alveolar tissue is associated with T cell reactivity,
pathological pulmonary macrophage activation, and auto-antibody production. Mesenchymal stem cells have been demonstrated to potently
suppress autoreactive T cells, inhibit macrophage activation, and autoantibody responses. Additionally, mesenchymal stem cells can be
purified in high concentrations from adipose stromal vascular tissue together with high concentrations of T regulatory cells, which in
animal models are approximately 100 times more potent than peripheral T cells at secreting cytokines therapeutic for COPD such as IL-10.
Additionally, use of adipose derived cells has yielded promising clinical results in autoimmune conditions such as multiple sclerosis;
and c) Pulmonary stem cells capable of regenerating damaged parenchymal tissue have been reported. Administration of mesenchymal stem
cells into neonatal oxygen-damaged lungs, which results in COPD-like alveoli dysplasia, has been demonstrated to yield improvements in
two recent publications.

 Based
on the above rationale for stem cell-based COPD treatments, we are proposing a 10 patient Phase I safety trial to assess ability of our
COPDcell, a type of umbilical cord derived stem cells to improve objective and quality of life parameters in patients with moderate to
severe COPD.

 MSCs
can be derived in large number from the Umbilical Cord (UC). COPDcells are a type of UC-MSCs, which can be utilized in the allogeneic
setting and have demonstrated safety and efficacy in clinical trials for a number of disease conditions including inflammatory and immune-based
diseases. UC-MSCs have been shown to inhibit inflammation and fibrosis in the lungs.

 Breast
Cancer Immunotherapy

 Recently
the Company announced the formation of a Spin-Off Company, Res Nova Bio, Inc., dedicated to the development of cancer inhibiting anti-angiogenesis
immunotherapies. Res Nova Bio has licensed from Therapeutic Solutions International intellectual property covering StemVacs-V which is
our iPSC derived platform technology announced in May of 2021. The technology utilizes pluripotent stem cells called iPSCs in order to
generate new cells which resemble tumor blood vessels that are made to act as a "therapeutic vaccine". Specifically, the
administration of StemVacs-V stimulates the immune system to selectively kill blood vessels that feed the tumor but not healthy blood
vessels. It is believed that for every 1 tumor blood vessel cell that is killed, 200-300 tumor cells are also killed as a result.

 In
addition to the license, the Company has transferred ownership of the IND titled " Treatment of Metastatic Breast Cancer
by StemVacs-V Cancer Immunotherapeutic" to Res Nova Bio with the primary objective being safety and feasibility of StemVacs-V administration
at 12 months as assessed by lack of adverse medical events. The secondary objective is efficacy as judged by tumor response, time to
progression, and immunological monitoring.

 Amyotrophic
Lateral Sclerosis

 In
December 2023, the Company announced the formation of ALS Biologics Inc, a subsidiary company dedicated to accelerating development of
the Company's assets related to Amyotrophic Lateral Sclerosis, a progressive motor neuron degenerative disease for which no cure
exists. The company was formed based on previous positive observations in patients treated with the Company's ALScell (JadiCell)
product under the Right to Try Law.

 The
ALScell (aka JadiCell) is unique in that it possesses features of mesenchymal stem cells, however, ALScells outperform
these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability.

 Epilepsy

 On
January 16, 2024, the Company announced the forming of Epilepsy Bio, Inc., focused on treatment methods for reducing and/or reversing
epilepsy through administration of mesenchymal stem cells to induce immune modulation and/or regenerative processes.

 Cellular
Manufacturing and Cell Banking

 On
October 18, 2021, the Company announced the formation of Allogen Biologics Inc, a wholly owned subsidiary of TSOI. Allogen Biologics
will house intellectual property and Standard Operating Procedures related to generation of the Company's existing and anticipated
cellular therapeutics. In addition, Allogen will house and maintain all relevant cell banks.

 On
May 10, 2022, Allogen Biologic, Inc, and Therapeutic Solutions International Inc, entered into an Exclusive Patent License Agreement
(EPLA) for Patent Application Serial No. 63/254,469, filed by Licensor and titled as: Umbilical Cord Derived Regenerative and Immune
Modulatory Stem Cell Populations.

 On
August 16, 2023, TSOI issued this press release "Therapeutic Solutions International Subsidiary Allogen Biologics Inc. Successfully
Manufactures JadiCell Master Cell Bank to Provide Cells for Right to Try Use and Phase III ARDS Clinical Trial".

 Now
that we have established our own Master Cell Bank with corresponding biomarker assays of CD73, CD90, CD105 >90%, and CD14, CD34, CD45
<10%, these aliquots, which are in process of 3rd party validation will remain in cryopreservation to age the cells for purposes of
required immuno-assays to clear phase 3 in the future when cells reach acceptable age to satisfy FDA. MCB was established in August 2023
and our estimate is next August 2024 we will have adequately aged the cells to obtain clearance for phase 3 IND.

 GOVERNMENT
REGULATION

 The
Company's business is subject to varying degrees of regulation by a number of government authorities in the United States, including
the United States Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and the Consumer Product Safety Commission.
The Company will be subject to additional agencies and regulations if it enters the manufacturing business. Various agencies of the state
and localities in which we operate and in which our products are sold also regulate our business, such as the California Department of
Health Services, Food and Drug Branch. The areas of our business that these and other authorities regulate include, among others:

 product
 claims and advertising;

 product
 labels;

 product
 ingredients; and

 how
 we package, distribute, import, export, sell and store our products.

 The
FDA, in particular, regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution and sale of vitamins
and other nutritional supplements in the United States, while the FTC regulates marketing and advertising claims. The FDA issued a final
rule called "Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body,"
which includes regulations requiring companies, their suppliers, and manufacturers to meet Good Manufacturing Practices in the preparation,
packaging, storage, and shipment of their products. Management is committed to meeting or exceeding the standards set by the FDA.

 The
FDA has also issued regulations governing the labeling and marketing of dietary and nutritional supplement products. They include:

 the
 identification of dietary or nutritional supplements and their nutrition and ingredient labeling;

 requirements
 related to the wording used for claims about nutrients, health claims, and statements of nutritional support;

 labeling
 requirements for dietary or nutritional supplements for which "high potency" and "antioxidant" claims are
 made;

 notification
 procedures for statements on dietary and nutritional supplements; and

 pre-market
 notification procedures for new dietary ingredients in nutritional supplements.

 The
Dietary Supplement Health and Education Act of 1994 (DSHEA) revised the existing provisions of the Federal Food, Drug and Cosmetic Act
concerning the composition and labeling of dietary supplements and defined dietary supplements to include vitamins, minerals, herbs,
amino acids, and other dietary substances used to supplement diets. DSHEA generally provides a regulatory framework to help ensure safe,
quality dietary supplements and the dissemination of accurate information about such products. The FDA is generally prohibited from regulating
active ingredients in dietary supplements as drugs unless product claims, such as claims that a product may heal, mitigate, cure, or
prevent an illness, disease or malady, trigger drug status.

 The
Company is also subject to a variety of other regulations in the United States, including those relating to taxes, labor, and employment,
import and export, and intellectual property.

 EMPLOYEES

 As
of December 31, 2023, we had three full-time employees, all non-union. We believe that our relations with our employees are good.

 COMPETITION

 The
bio-technology, bio-pharma, and nutraceutical industries are subject to rapid technological change. Competition from domestic and foreign
companies, large pharmaceutical companies and other interested businesses is intense and expected to increase. A number of companies
with significantly greater resources are pursuing the development of pharmaceuticals, biologics, and nutraceuticals in our targeted areas.

 ITEM
 1A

 RISK
 FACTORS

 As
a smaller reporting company, we are not required to provide a statement of risk factors. However, we believe this information may be
valuable to our shareholders for this filing. We reserve the right to not provide risk factors in our future filings. Our primary risk
factors and other considerations include:

 This
Annual Report on Form 10-K contains forward-looking statements concerning our future programs, expenses, revenue, liquidity, and cash
needs as well as our plans and strategies. These forward-looking statements are based on current expectations, and we assume no obligation
to update this information, except as required by applicable laws and regulations. Numerous factors could cause actual results to differ
significantly from the results described in these forward-looking statements, including the following risk factors.

 Internal
Control

 Our
management has concluded that our internal control over financial reporting is not effective. Material weaknesses in our internal control
over financial reporting could cause our financial reporting to be unreliable and could lead to misinformation being disseminated to
the public.

 Our
management concluded that as of December 31, 2023, our internal control over financial reporting was not effective, and that material
weaknesses existed in the following areas as of December 31, 2023:

 (1)

 we
 do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding
 certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will
 continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;

 (2)

 we
 have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process,
 transaction or account changes, and the performance of account reconciliations and approval; and

 (3)

 we
 have ineffective controls over the period end financial disclosure and reporting process caused by reliance on third-party experts
 and/or consultants and insufficient accounting staff.

 Based
on our current plan, we believe we will need additional capital to support our operations.

 Based
on our current business plan, we believe that our cash and cash equivalents at December 31, 2023 will not be sufficient to meet our anticipated
cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Annual Report
on Form 10-K. Our current commercialization of products and clinical trial strategy will undergo continual prioritization and in the
future we may adjust our commercialization efforts to preserve our existing cash. We need to raise additional capital to fund our operations.
We may raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds
may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may be
required to delay, reduce the scope of, or curtail, our operations. To the extent that we raise additional funds by issuing equity securities,
our shareholders will experience dilution, and debt financing or other preferred equity instruments, if available, may involve restrictive
covenants.

 There
is substantial doubt about our ability to continue as a going concern.

 Our
recurring losses from operations raise substantial doubt about our ability to continue as a going concern, and as a result, our independent
registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year
ended December 31, 2023, with respect to this uncertainty. This going concern uncertainty, and any future going concern uncertainty,
could materially limit our ability to raise additional capital. We have incurred significant losses since our inception, and it is possible
we will never achieve future profitability. As a result, we continue to incur significant general and administrative expenses related
to our operations. As a result, we have incurred substantial net losses to date. Our net losses for the years ended December 31, 2022,
and 2022 were $2.7 million and $3.7 million, respectively. As of December 31, 2023, we had an accumulated deficit of $20.1 million. The
perception that we may not be able to continue as a going concern may cause potential partners or investors to choose not to deal with
us due to concerns about our ability to meet our contractual and financial obligations.

 We
may not be able to effectively manage our potential growth and the execution of our business plan.

 Our
potential growth and the execution of our business plan together are likely to place significant strain on our managerial, operational,
and financial resources. To effectively manage our potential growth and execute our business plan, we will need to, among other things:

 There
can be no assurance that we will be able to accomplish any or all of the above goals. If we prove unable to effectively execute our business
plan or manage our growth, it is likely to have a material adverse effect on our business, financial condition, including liquidity and
profitability, and our results of operations.

 If
our proposed product sales model does not successfully operate at a profit our growth strategy may be impeded.

 To
effectively expand and meet our growth objectives our products sales model must be executed upon in a profitable manner. Profitability
is dependent upon a variety of factors, some beyond our control, including, but not limited to the amount of traffic we can consistently
attract to our brand, to retail sales in "brick and mortar" retailers, to our website, and our ability to stock or otherwise
make available products that our customers purchase, our ability to stock or otherwise make available the best new products as they enter
the market, our ability to provide consistent and superior customer service, the general economic conditions, particularly in the U.S.,
that could impact the amount of money customers spend collectively on the products we sell, and/or that could reduce the amount of money
our average customer spends, and/or could reduce the number or frequency of repeat orders for products, and/or could result in customers
finding products in other venues if they can find those products for a lower price. Other factors that could impact our ability to execute
on our business model in a profitable manner include, but are not limited to, competition in our markets, recruiting, training and retaining
qualified personnel and management, maintenance of required local, state and federal governmental approvals and permits, costs associated
with principal component products and supplies, delivery shortages or interruptions, consumer trends, our ability to finance operations
externally, changes in supply or prices of the products we sell and disruptions or business failures among our product suppliers, distributors,
warehouses or shippers. Any failure to operate in a profitable manner could hurt our ability to meet our growth objectives by attracting
licensees, and our business, financial condition, including liquidity and profitability, and our results of operations would be negatively
affected.

 We
face significant competition for our products.

 The
markets in which we operate are intensely competitive, continually evolving and, in some cases, subject to rapid change. Our competitors
include:

 traditional
 and well established companies with recognized and well patronized brands in the nutritional supplements and health products industry
 segment;

 entrenched
 nutritional supplements and health products companies with well known customer on-line services and portals and other high-traffic
 web sites that provide sales access to healthcare and nutritional supplements and related products; and

 companies
 that focus on providing on-line and/or off-line healthcare related content, including some that promote competitor brands.

 retain
 additional personnel across several departments in the Company;

 develop
 strong customer loyalty for new products in a crowded competitive marketplace;

 continue
 to establish and continue to increase awareness of our brands;

 price
 our products and services at points which will allow us to maximize sales while at the same time maximizing gross profit margins;

 establish,
 maintain, expand and manage multiple relationships with various vendors, strategic partners, licensees and other third parties, including
 suppliers of the products we sell on our website and elsewhere, warehousing distributors, shipping companies and others;

 rapidly
 respond to competitive developments, particularly when new high-demand products become available;

 build
 an operations structure to support our business and provide efficient and effective customer service and support;

 expand
 our IT infrastructure to respond to increasing customer traffic to our website, demand for content from site users and to manage
 growing e-commerce transactions;

 establish
 and maintain effective financial and management controls, reporting systems and procedures;

 control
 our expenses;

 provide
 competitive employee salaries and benefit packages; and,

 avoid
 lawsuits and other adverse claims.

 Many
of our competitors have greater financial, technical, product development, marketing and other resources than we do. These companies
may be better known than we are and have more customers than we do. We cannot provide assurance that we will be able to compete successfully
against these companies or any alliances they have formed or may form. If we are unable to compete with one or more of our competitors,
our growth strategy may be impeded, which could negatively affect our business, financial condition, including liquidity and profitability,
and our results of operations.

 Government
regulation could adversely affect our business.

 Our
products and their associated component ingredients are subject to existing and potential government regulation. Our failure, or the
failure of our business partners or third party providers, to accurately anticipate the application of laws and regulations affecting
our products and the manner in which we deliver them, or any failure to comply, could create liability for us, result in adverse publicity,
or negatively affect our business. In addition, new laws and regulations, or new interpretations of existing laws and regulations, may
be adopted with respect to consumer protection and other issues, including pricing, products liability, copyrights and patents, distribution
and characteristics and quality of products and services. We cannot predict whether these laws or regulations will change or how such
changes will affect our business. Any of this government regulation could impact our growth strategy, which could negatively affect our
business, financial condition, including liquidity and profitability, and our results of operations.

 Third
parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expense
or be prevented from providing certain services, and which may otherwise harm our business.

 We
could be subject to claims that we are misappropriating or infringing intellectual property, trade secrets or other proprietary rights
of others. These claims, even if not meritorious, could be expensive to defend and divert management's attention from our operations.
If we become liable to third parties for infringing these rights, we could be required to pay substantial damage awards and to develop
non-infringing products, obtain a license or cease selling the products that use or contain the infringing intellectual property. We
may be unable to develop non-infringing products or obtain a license on commercially reasonable terms, or at all. Any claims against
our company for infringement could impede our growth strategy, which could negatively affect our business, financial condition, including
liquidity and profitability, and our results of operations.

 We
may be subject to claims brought against us as a result of product associated content we provide.

 Consumers
are reasonably expected to access health-related information regarding our products through our on-line web site. If our content, or
content we obtain from third parties, contains inaccuracies, it is possible that consumers or others may sue us for various causes of
action. Although our planned web site contains terms and conditions, including disclaimers of liability, that are intended to reduce
or eliminate our liability, the law governing the validity and enforceability of on-line agreements with consumers that provide the terms
and conditions for use of our public or private portals are unenforceable. A finding by a court that these agreements are invalid and
that we are subject to liability could harm our business and require costly changes to our business. We have planned editorial procedures
in place to provide quality control of the information that we publish or provide. However, we cannot assure you that our editorial and
other quality control procedures will be sufficient to ensure that there are no errors or omissions in particular content. Even if potential
claims do not result in liability to us, the fact that we would need to investigate and defend against these claims could be expensive
and time consuming and could divert management's attention away from our operations. In addition, our business is in part based
on establishing a reputation amongst consumers that our portals as trustworthy and dependable sources of healthcare information. Allegations
of impropriety or inaccuracy, even if unfounded, could therefore harm our reputation and business, which could negatively affect our
business, financial condition, including liquidity and profitability, and our results of operations.

 Changes
in commodity and other operating costs or supply chain and business disruptions could adversely affect our results of operations.

 Changes
in product costs are a part of our business; any increase in the prices that suppliers charge for their products could adversely affect
our operating results. We remain susceptible to increases in prices as a result of factors beyond our control, such as general economic
conditions, seasonal fluctuations, weather conditions, demand, safety concerns, product recalls, labor disputes and government regulations.
We rely on third-party distribution companies to deliver ingredients to our manufacturers and ultimately our products to customers. Interruption
of distribution services due to financial distress or other issues could adversely affect our operations.

 We
face substantial competition in attracting and retaining qualified senior management and key personnel and may be unable to develop and
grow our business if we cannot attract and retain such senior management and key personnel.

 As
an early stage company, our ability to develop and grow our business, to a large extent, depends upon our ability to attract, hire and
retain highly qualified and knowledgeable senior management and key personnel who possess the skills and experience necessary to satisfy
our business needs. Our ability to attract and retain such senior management and key personnel will depend on numerous factors, including
our ability to offer salaries, benefits and professional growth opportunities that are comparable with and competitive to those offered
by more established companies operating in our marketplace. We may be required to invest significant time and resources in attracting
and retaining additional senior management and key personnel as needed. Moreover, many of the companies with which we will compete for
any such individuals have greater financial and other resources, affording them the ability to undertake more extensive and aggressive
hiring campaigns, than we can. The normal running of our operations may be interrupted, and our financial condition and results of operations
negatively affected, as a result of any inability on our part to attract or retain the services of qualified and experienced senior management
and key personnel, or should our prospective key personnel refuse to serve, or, once appointed, leave prior to a suitable replacement
being found.

 Risks
Associated With Our Restricted Securities

 Because
there is currently a limited public trading market for our common stock, investor may not be able to resell stock.

 Our
stock is now traded in OTC Markets under the stock symbol TSOI, which results in a very illiquid and limited market for our common stock.

 There
is currently no liquid trading market for our common stock and we cannot ensure that one will ever develop or be sustained.

 The
trading market for our common stock is currently not liquid. We cannot predict how liquid the market for our common stock might become.
Our common stock is quoted in OTC Markets under the symbol TSOI.

 Our
common stock may be deemed a "penny stock", which would make it more difficult for investors to sell their shares.

 Our
common stock is subject to the "penny stock" rules adopted under the Exchange Act. The penny stock rules apply to companies
whose common stock is not listed on the NASDAQ Stock Market or other national securities exchange and trades at less than $4.00 per share,
other than companies that have had average revenue of at least $6,000,000 for the last three years or that have tangible net worth of
at least $5,000,000 ($2,000,000 if the company has been operating for three or more years). These rules require, among other things,
that brokers who trade penny stock to persons other than "established customers" complete certain documentation, make suitability
inquiries of investors and provide investors with certain information concerning trading in the security, including a risk disclosure
document and quote information under certain circumstances. Many brokers have decided not to trade penny stocks because of the requirements
of the penny stock rules and, as a result, the number of broker-dealers willing to act as market makers in such securities is limited.
If we remain subject to the penny stock rules for any significant period, it could have an adverse effect on the market, if any, for
our securities and investors may find it more difficult to dispose of our securities.

 Offers
or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

 If
our stockholders have the right to sell substantial amounts of common stock in the public market, e.g. upon the expiration of any statutory
holding period under Rule 144, it could create a circumstance commonly referred to as an "overhang" and in anticipation of
which the market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring,
also could make our ability to raise additional financing through the sale of equity or equity-related securities in the future, at a
time and price that we deem reasonable or appropriate, more difficult.

 The
elimination of monetary liability against our directors and officers under the Company's Articles of Incorporation and Nevada law,
and the existence of indemnification rights to our directors, officers and employees, may result in substantial expenditures by the Company.

 Article
6 of our Articles of Incorporation exculpates our directors and officers from certain monetary liabilities. Article 7 of our Articles
of Incorporation provides that we shall indemnify all directors (and all persons serving at our request as a director or officer of another
corporation) to the fullest extent permitted by Nevada law.

 Further
pursuant to Article 7, the expenses of the indemnified person incurred in defending a civil suit or proceeding must be paid by us as
incurred and in advance of the final disposition of the action, suit, or proceeding under receipt of an undertaking by or on behalf of
the indemnified person to repay the amount if it is ultimately determined by a court of competent jurisdiction that he or she is not
entitled to be indemnified by us.

 The
foregoing indemnification obligations could result in us incurring substantial expenditures, which we may be unable to recoup. These
provisions and resultant costs may also discourage us from bringing a lawsuit against directors and officers for breaches of their fiduciary
duties even though such actions, if successful, might otherwise benefit us and our stockholders.

 Public
company compliance may make it more difficult to attract and retain officers and directors.

 The
Sarbanes-Oxley Act and related rules implemented by the SEC have required changes in corporate governance practices of public companies.
As a public entity, these rules and regulations increase compliance costs and make certain activities more time-consuming and costly.
As a public entity, these rules and regulations also make it more difficult and expensive for us to obtain director and officer liability
insurance and we may be required to accept reduced policy limits and coverage. As a result, it may be more difficult for us to attract
and retain qualified persons to serve as directors or as executive officers.

 We
do not plan to pay any cash or stock dividends in the foreseeable future.

 The
payment of dividends upon our capital stock is solely within the discretion of our future board of directors and is dependent upon our
financial condition, results of operations, capital requirements, restrictions contained in our future financing instruments and any
other factors our board of directors may deem relevant. We have never declared or paid any cash or stock dividends on our capital stock
and we currently anticipate that we will retain earnings, if any, to finance the development and expansion of our business and, as such,
do not intend on paying any cash or stock dividends in the foreseeable future.

 ITEM
 1B

 CYBERSECURITIES

 Risk
Management and Strategy

 The
Company invests in information technology systems for its e-commerce and Corporate websites. Such investments, including the implementation
of technology updates, improves the Company's customers' experience, and supports both compliance and internal controls. The Company
is actively attempting to identify and manage cybersecurity risks. Protecting company data, non-public customer and employee data, and
the systems that collect, process, and maintain this information is a Company Priority.

 Cybersecurity
Risk

 In
recent years there has been an increased risk of information and security risks due to increased sophistication and activities of perpetrators
of cyber attacks. The computers are used for our everyday business operations including mobile devices and other online means of activities
to connect with our customers, employees, suppliers, and other parties. This extensive use gives rise to cybersecurity risks such as
system disruption, theft, and release of confidential information. There is sensitive information stored in the systems and intellectual
property, including employees, customers and other financial information.

 In
the future we may be required to expend additional resources to continue to enhance information security measures to investigate and
remediate any information security vulnerabilities. We can provide no assurance that the measures we have implemented to prevent security
breaches and cyber incidents will be effective in the event of a cyber-attack. Our Directors do not have enough expertise to monitor
and manage such risks and will need to rely upon others to help us stay vigilant, process, report, and remediate any incidents.

 ITEM

 PROPERTIES.

 On
December 17, 2020, Therapeutic Solutions International, Inc. Board of Directors made a decision to move our corporate headquarters to
Elk City, Idaho 83525 and has purchased real property at 701 Wild Rose Lane and 50 Bullock Lane, Elk City Idaho 83525. The Company continues
to maintain a satellite office at the current address of 4093 Oceanside Blvd., Suite B, Oceanside CA, 92056.

 ITEM

 LEGAL
 PROCEEDINGS.

 From
time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties, or
injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome
in any specific period could have a material adverse effect on our results of operations for that period or future periods.

 However,
as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a
material adverse effect on our financial condition or results of operations.

 ITEM

 MINE
 SAFETY DISCLOSURES.

 No
disclosure required.

 PART
II

 ITEM

 MARKET
 FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 Our
stock is now traded in OTC Markets under the stock symbol TSOI, which results in a very illiquid and limited market for our common stock.
As of the date of Annual Report on Form 10-K there are approximately 213 stockholders of record of our common stock.

 The
following table sets forth the quarterly high and low closing sales prices for our common stock from January 1, 2022 through December
31, 2023.

 Quarter Ended

 High

 Low

 $
 0.0012

 $
 0.001

 September 30, 2023

 $
 0.018

 $
 0.0014

 June 30, 2023

 $
 0.022

 $
 0.0021

 March 31, 2023

 $
 0.0027

 $
 0.0023

 $
 0.0063

 $
 0.0055

 September 30, 2022

 $
 0.014

 $
 0.0121

 June 30, 2022

 $
 0.022

 $
 0.0199

 March 31, 2022

 $
 0.0257

 $
 0.0241

 Dividends

 We
did not declare or pay dividends during 2022 to 2023.

 Issuances
of Unregistered Securities

 In
2022, we issued 44,500,000 shares of common stock for an investment in the Company's Private Placement of $445,000.

 In
2022, we issued 28,302,577 shares of common stock, valued at $537,778 for consulting services.

 In
2022, we issued 4,812,259 shares of common stock, valued at $67,399 for salaries.

 In
2022, we issued 4,110,000 shares of common stock, valued at $51,742 for land development.

 In
2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for an license.

 In
2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $1,313,772.

 In
2023, we issued 556,632,297 shares of common stock for an investment in the Company's Private Placement of $790,432.

 In
2023, we issued 115,527,394 shares of common stock, valued at $176,911 for consulting services.

 In
2023, we issued 64,081,632 shares of common stock, valued at $110,000 for salaries.

 In
2023, we issued 60,000,000 shares of common stock, valued at $96,000 for land development.

 In
2023, we issued 389,304,825 shares of common stock for the conversion of convertible notes of $928,816.

 ITEM

 SELECTED
 FINANCIAL DATA.

 Not
required for a "smaller reporting company".

 ITEM

 MANAGEMENT'S
 DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 The
following discussion and analysis should be read in conjunction with the consolidated Financial Statements and Notes thereto appearing
elsewhere in this Annual Report.

 Overview

 Currently
the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to
upregulate (make more active) or downregulate (make less active) one's immune system.

 Activating
one's immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections
and to prevent illness. Additionally, inhibiting one's immune system is vital for reducing inflammation, autoimmune disorders and
allergic reactions.

 TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
and for daily health.

 Nutraceutical
Division. TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune, is a multi-patented
synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone. QuadraMune has been shown to increase Natural
Killer Cell activity and healthy Cytokine production. Our synergistic blend of ingredients helps the immune system fight off common and
complex ailments and promote healthy T Cell activity. Recently the Company was approved to sell certain nutraceuticals on the Amazon
Platform.

 Cellular
Division. SOI recently obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE), traumatic brain injury (TBI), and lung pathology.

 The
stem cell licensed, termed "JadiCell" is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability.

 Chronic
Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and
is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression,
depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal
cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment
to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021, the Company received an IND Serial # 27377 for a clinical
trial of 10 patients with CTE.

 On
August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for
registration of the Company's JadiCell universal donor stem cell as a treatment for COVID-19 associated lung failure under
IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell to other types of stem cells including
bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell was shown to be 100% effective in saving the lives of
COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In
patients over the age of 85 the survival rate was 91%.

 In
addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs
resulted in enhanced activity of a type of immunological cell called "natural killer" cells, otherwise known as "NK
cells."

 The
Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells
called dendritic cells in a manner so that upon injection they reprogram the body's NK cells.

 Most
recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system
to kill blood vessels feeding cancer but sparing healthy blood vessels. These discoveries are an extension of previous findings from
the Company showing that StemVacs is capable of suppressing new blood vessel production.

 On
May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Using JadiCell Universal Donor Adult Stem Cells under IND Serial # 28508.

 Results
of Operations

 We
had a net loss of approximately $2.2 million in 2023 compared to a net loss of approximately $3.8 million in 2022.

 Net
sales decreased $107,773 from $206,767 to $98,994, for the years ended December 31, 2022 and 2023 respectively. This decrease was mainly
due to an decrease in sales of the Company's nutraceutical line of products.

 Cost
of goods sold decreased $42,672, from $79,440 to $36,768, for the years ended December 31, 2022 and 2023, respectively. This decrease
was mainly due to lower net sales of the Company's nutraceutical line of products in 2023 vs 2022.

 Operating
expenses for the years ended December 31, 2023 and 2022 were approximately $2 million and $3.4 million, respectively, a decrease of
$1.4 million. This decrease was mainly due a combination of less selling expenses as sales decreased, and less research and development as
we paid out more for patent expenses.

 General
and administrative expenses decreased approximately $23,000, from $497,000 to $474,960, for the years ended December 31, 2022 and 2023,
respectively. This decrease was mainly due to a selling expenses decreased due to less sales.

 Salaries,
wages and related expenses decreased approximately $12,000, from $445,000 to $433,000, for the years ended December 31, 2022 and 2023,
respectively. This decrease was mainly due to using an outside manufacturer instead of manufacturing in house.

 Consulting
fees decreased approximately $464,000, from $613,000 to $149,000 for the years ended December 31, 2022 and 2023, respectively, due
to expired 2 year consulting agreements which were not renewed.

 Legal
and professional fees increased approximately $31,000, from $400,000 to $431,000 for the years ended December 31, 2022 and 2023, respectively,
due to a increase in general counsel services handling filings with the SEC and new subsidiaries.

 Research
and development costs decreased approximately $891,000 from $1,452,000 to $561,000, for the years ended December 31, 2022 and 2023, respectively.
This decrease was mainly due more patent fees and less cash for research and development.

 Total
loss from derivatives liabilities increased approximately $168,000 from a loss of $131,000 to a gain of $37,000 for the years ended December
31, 2022 and 2023, respectively. This increase was due to a derivative liability expense from certain convertible notes in 2023 compared
to 2022.

 Total
change in fair value of derivatives liabilities decreased approximately $309,000 from a gain of $291,000 to a loss of $18,000 for the
years ended December 31, 2022 and 2023, respectively. This decrease was due to a derivative liability expense from certain convertible
notes in 2023 compared to 2022.

 Net
interest expense increased approximately $223,000 from $646,000 to $423,000 for the years ended December 31, 2022 and 2023, respectively.
This increase was mainly due to increased debt balances.

 Liquidity
and Capital Resources

 We
have experienced recurring losses over the past years which have resulted in accumulated deficits of approximately $20 million and
a working capital deficit of approximately $1.8 million at December 31, 2023. These conditions raise significant doubt about the Company's
ability to continue as a going concern. The Company's ability to continue as a going concern is contingent upon its ability to
secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue
to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain
such on terms satisfactory to the Company, if at all.

 There
is no guarantee we will receive the required financing to complete our business strategies, and it is uncertain whether future financing
will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop
or expand our operations.

 As
of December 31, 2023, we had approximately $28,000 in cash and cash equivalents, representing a decrease in cash and cash equivalents
of approximately $18,000 from December 31, 2022. Sources of cash were predominantly from the sale of equity and debt. We anticipate that
our current sources of liquidity, including cash and cash equivalents, together with our current projections of cash flow from operating
activities, will provide us with liquidity into the end of 2023.

 Cash
Flows from Operating Activities

 Our
cash flows from operating activities are significantly affected by our cash outflows to support the growth of our business in areas such
as R&D and G&A expenses. Our operating cash flows are also affected by our working capital needs to support personnel related
expenditures, accounts payable and other current assets and liabilities.

 During the year ended December 31, 2023, cash used in operating activities was $1,055,290, which was primarily the result of our net loss
incurred of $2,224,700, partially offset by increases in the various accounts payable and accrued liability accounts totaling $143,963
and non-cash expenses including stock-based compensation of $278,752 change in value on derivative liabilities of $17,836, amortization
of debt discount of $384,744 and amortization and depreciation of $311,778.

 Cash
Flows from Investing Activities

 During the year ended December 31, 2023, net cash used by investing activities was $24,000, compared to $0 during the year ended December
31, 2022. The decrease of approximately $24,000 in net cash used by investing activities is mainly attributable to a purchase of property
and equipment and an issuance of notes receivables from the Company's subsidiaries

 Cash
Flows from Financing Activities

the year ended December 31, 2023, net cash provided by financing activities was $1,077,676, compared to $943,088 during the year ended
December 31, 2022. The increase of approximately $357,000 in net cash provided by financing activities is mainly attributable to an increase
of $1,012,932 in cash received from the sale of common stock. Other cash flows provided by financing activities during the year ended
December 31, 2023 included proceeds from convertible notes payable to related and third parties totaling $292,000 offset by payments
on notes payable to related parties and third parties of $5,000.

 Off-Balance
Sheet Arrangements.

 We
currently do not have any off-balance sheet arrangements.

 ITEM
 7A

 QUANTITATIVE
 AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 Not
required for a "smaller reporting company".

 ITEM

 FINANCIAL
 STATEMENTS AND SUPPLEMENTARY DATA.

 Our
financial statements and the accompanying notes that are filed as part of this Annual Report on Form 10-K are listed and set forth beginning
on page F-1 immediately following the signature page of this Form 10-K.

 ITEM

 CHANGES
 IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 None.

 ITEM
 9A

 CONTROLS
 AND PROCEDURES

 Disclosure
Controls and Procedures

 Disclosure
controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our
reports filed or submitted under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act is accumulated and
communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure.

 At
the end of the period covered by this Annual Report on Form 10-K for the fiscal year ended December 31, 2023, an evaluation was carried
out under the supervision of and with the participation of our management, including the Chief Executive Officer ("CEO"),
of the effectiveness of the design and operations of our disclosure controls and procedures (as defined in Rule 13a-15I and Rule 15d-15(e)
under the Exchange Act). Based on that evaluation the CEO has concluded that as of the end of the period covered by this Annual Report,
our disclosure controls and procedures were not effective.

 Internal
Control Over Financial Reporting

 Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is defined in Rule 13a- 15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or
under the supervision of, a company's principal executive and principal financial officers and effected by a company's board
of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those
policies and procedures that:

 Pertain
to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
of the company;

 Provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and

 Provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's
assets that could have a material effect on the financial statements.

 All
internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the
Company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect
to financial statement preparation and presentation.

 Our
management, including the Chief Executive Officer, assessed the effectiveness of our internal control over financial reporting as of
December 31, 2023. In making our assessment, we used the framework and criteria set forth by the Committee of Sponsoring Organizations
of the Treadway Commission("COSO") (2013) in Internal Control-Integrated Framework. Based on that assessment, our management
has identified certain material weaknesses in our internal control over financial reporting.

 (1)

 Our
 management concluded that as of December 31, 2023, our internal control over financial reporting was not effective, and that material
 weaknesses existed in the following areas as of December 31, 2023 we do not employ full time in-house personnel with the technical
 knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect
 to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or
 consultants to gain a thorough understanding of these transactions;

 (2)

 we
 have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process,
 transaction or account changes, and the performance of account reconciliations and approval;

 (3)

 we
 have ineffective controls over the period end financial disclosure and reporting process caused by reliance on third-party experts
 and/or consultants and insufficient accounting staff.

 Changes
in Internal Control Over Financial Reporting

 No
substantial changes in our internal control over financial reporting occurred during 2023 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting, except that we have increased our use of external accounting
services, adopted policies to improve timely reviews by management and coordination with accounting consultants, and engaged corporate
and securities legal counsel with better capabilities than our previous provider's.

 ITEM
 9B

 OTHER
 INFORMATION.

 None

 PART
III

 ITEM

 DIRECTORS,
 EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 The
Company's executive officers and directors and their respective ages as of December 31, 2023 are as follows:

 Directors:

 Name
 of Director

 Age

 Timothy
 G. Dixon

 Dr.
 Thomas E. Ichim

 Executive
Officers:

 Name

 Position

 Age

 Executive
 Officers:

 Timothy
 G. Dixon

 President
 and Chief Executive Officer

 Famela
 Ramos

 Vice
 President

 James
 Veltmeyer, MD

 Chief
 Medical Officer

 Feng
 Lin, MD, PhD

 Chief
 Scientific Officer

 The
term of office for each director is one year, or until the next annual meeting of the stockholders.

 Biographical
Information

 Timothy
G. Dixon

 Mr.
Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. He also currently
serves as Chairman of Campbell Neurosciences, Inc., Allogen Biologics, Inc., ALS Biologics, Inc., CTE Biologics, Inc., Epilepsy Biologics,
Inc., Res Nov Bio, Inc., VasoSome Vascular, Inc., and Breathe Biologics, Inc., all subsidiaries of TSOI. Mr. Dixon previously served
as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon also
has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration (FDA), as well as many
international regulatory bodies. Mr. Dixon is inventor and co-inventor of 75+ patents and patents pending..

 Thomas
E. Ichim, Ph. D.

 Dr.
Ichim was appointed to the Board of Directors on January 22, 2016. Dr. Ichim also serves as CEO and Director of Campbell Neurosciences,
Inc., Allogen Biologics, Inc., ALS Biologics, Inc., Breathe Biologics, Inc., and Director of Allogen Biologics, Inc., Epilepsy Biologics,
Inc., Res Nov Bio, Inc., and VasoSome Vascular, Inc., all subsidiaries of TSOI. Dr. Ichim is a seasoned biotechnology entrepreneur with
a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp,
ToleroTech Inc, bioRASI, and OncoMune LLC. To date, he has published 121 peer-reviewed articles and is co-editor of the textbooks "RNA
Interference: From Bench to Clinical Translation" and "Immuno-Oncology Text Book."

 Dr.
Ichim is an ad-hoc editor and sits on several editorial boards. Dr. Ichim is an inventor on over 300 patents and patent applications.
Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim
spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial
Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with
the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.

 Dr.
Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, an MSc in Microbiology and Immunology a University
of Western Ontario, London, Ontario, Canada and a Ph. D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

 James
Veltmeyer, M.D., – Chief Medical Officer

 Dr.
Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of
Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing
36 doctors.

 Dr.
Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his
colleagues in the San Diego County Medical Society as a "Physician of Exceptional Excellence," the most prestigious honor
awarded to a "Top Doctor" in San Diego County. He is among a select group of San Diego physicians who was chosen four of
the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department
of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

 Feng
Lin, MD, Ph. D., – Chief Scientific Officer

 Dr.
Lin has a stellar track record of drug development in the area of immunology innumo-oncology having worked with the public company Inovio
Pharmaceuticals, where he developed technologies for gene delivery and therapeutic DNA vaccines against cancer and infectious diseases
in both R&D and clinical settings. Subsequently, Dr. Lin served as Director of Chinese Operations for MediStem Inc, which was acquired
by Intrexon in May 2014. It was the rapid clinical translation model developed by Dr. Lin at MediStem that resulted in the company's
accelerated FDA clearance to begin clinical trials, which resulted in the sale of the company.

 Dr.
Lin received his postdoctoral training at the Sanford-Burnham Medical Research Institute and his MD and Ph. D. at the Xiangya Medical
School of Central South University, China. He has authored over 20 peer-reviewed scientific publications, including several in top journals
such as Science, Cell, and Cancer Cell. He holds several patents.

 Famela
Ramos – Vice President Business Development

 Famela
Ramos is a Nurse, a Researcher, and a Politician. Famela was running for Congress in the 53nd Congressional District. Ms. Ramos came
to the United States from the Philippines at the age of two, when her father joined the United States Navy. Her parents worked tirelessly
to support the family of 5 children, all of which became successful entrepreneurs and Government Employees. As a nurse, Famela has experience
from the beginning of life, having practiced in pediatric nursing, to the end of life, having worked as a hospice nurse. Her excellence
in nursing and research is attested by 7 peer reviewed publications that she collaborated with Academy and Industry in advancing cutting
edge research in immunology and regenerative medicine.

 The
first paper, was a collaboration with the Moores Cancer Center and several biotechnology companies, describing the state of the art in
cancer immunotherapy, and proposing future directions. The second paper discussed the possibility of stimulating regeneration of injured
lung stem cells using specific types of laser and light based interventions, this was a collaboration between the University of Utah
and the University of California, San Diego. The third paper, a collaboration between a nutraceutical company and Indiana University,
demonstrated the beneficial effects of a nutritional supplement on circulating stem cells in healthy volunteers. The fourth publication
was the first successful use of two different types of stem cells in a patient with heart failure, which resulted in a profound improvement.
The fifth publication is a report of 114 patients that were treated with umbilical cord blood stem cells and demonstrated safety and
signals of efficacy in collaboration with a Chinese Biotech company. The sixth publication was successful treatment of a spinal cord
injury patient with stem cells. The seventh publication was the basis for an investigational new drug (IND) application to the FDA, describing
use of fat stem cells to treat aplastic anemia.

 Ms.
Ramos has established the Right to Try Foundation, which assists companies in utilizing this new law that allows for accelerated patient
access to experimental medication. Through this Foundation Ms Ramos facilitated the first utilization of a cancer vaccine in the United
States, and has been assisting both public and private companies. Most recently the Foundation has collaborated on filing new patents
for means of implementing the Right to Try Law. Ms. Ramos is a board member of Silent Voices, a Pregnancy Resource Center that provides
counselling to woman in emergency pregnancies, alternatives to abortion, and for woman that do choose abortion, post abortion support.
Ms. Ramos has been endorsed by business and community leaders as well as nationally known athletes including Dr. Peter Farrell, founder
of Resmed, a $18 billion company, and Wes Chandler, an NFL Hall of Fame San Diego Charger.

 Information
with Respect to Our Board of Directors

 The
following is a brief description of the structure and certain functions of our Board of Directors. Each of the current directors is serving
until his respective successor is duly elected, subject to earlier resignation. We do not have standing audit, compensation or nominating
committees of our Board of Directors. However, the full Board of Directors performs all of the functions of a standing audit committee,
compensation committee and nominating committee.

 Audit
Committee Related Function

 We
do not have a separately designated standing audit committee in place. Our full Board of Directors currently serves in that capacity.
This is due to the small number of members of our Board of Directors, the small number of executive officers involved with our company,
and the fact that we operate with few employees. Our Board of Directors will continue to evaluate, from time to time, whether a separately
designated standing audit committee should be put in place. We do not have an audit committee charter.

 The
Board of Directors reviews with management and the Company's independent public accountants the Company's financial statements,
the accounting principles applied in their preparation, the scope of the audit, any comments made by the independent accountants upon
the financial condition of the Company and its accounting controls and procedures and such other matters as the Board of Directors deems
appropriate. Because our common stock is traded on the OTC Markets Pink Sheet, we are not subject to the listing requirements of any
securities exchange regarding audit committee related matters.

 The
Board of Directors consisted of two directors: Mr. Dixon and Dr. Ichim. Because we do not have an audit committee at all, we disclose
that we do not have any "audit committee financial expert" serving on an audit committee.

 Compensation
Committee Related Function

 We
do not currently have a standing compensation committee, and do not have a compensation committee charter. The full Board of Directors
currently has the responsibility of reviewing and establishing compensation for executive officers and making policy decisions concerning
salaries and incentive compensation for executive officers of the Company.

 The
Company's executive compensation program is administered by the Board of Directors, which determines the compensation of the Chief/Executive
Officer/President and the Chief Financial Officer of the Company. In reviewing the compensation of the individual executive officers,
the Board of Directors considers the recommendations of the Chief Executive Officer, other market information and current market conditions,
as well as any existing employment agreements with them.

 Nominating
Committee Related Function

 We
do not currently have a standing nominating committee. We have not adopted procedures by which security holders may recommend nominees
to serve on our board of directors.

 SCIENTIFIC
ADVISORY BOARD

 The
following are members of the Company's Scientific Advisory Board as of December 31, 2023:

 Dr.
Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair, Department of Translational Neuro-Oncology
and Neurotherapeutics, John Wayne Cancer Institute.

 He
is also Director of Neuro-Oncology, Providence Saint John's Health Center and Member, Los Angeles Biomedical Research Institute.
Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and
an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. He is
on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute,
Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews,
or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences biotech
startups.

 Dr.
Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to
treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding
of the disease. A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and
novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain
tumors and eradicate the disease.

 Dr.
Francesco Marincola joined Kite in 2021 as Global Head of Cell Therapy Research. Before joining Kite, Francesco was President and
Chief Scientific Officer at Refuge Biotechnologies where responsible for the development and implementation of research and clinical
development strategies for adoptive cell therapy products and lead therapeutic programs based on nuclease deactivated CRISPR circuits.
He is also a National Institutes of Health (NIH) tenured senior investigator in cancer immunotherapy and biomarker research, and spent
23 years at the NIH, including 15 years as the Chief of the Infectious Disease and Immunogenetics Section at the NIH Clinical Center.
Previously, he also served as a distinguished research fellow in immune oncology discovery at AbbVie and as Chief Research Officer at
Sidra Research in Doha, Qatar.

 The
former President of the Society for Immunotherapy of Cancer (SITC; 2013-2014), Francesco currently serves as Editor-in-Chief for several
prominent peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications and Immunotherapy,
and is the author of more than 600 peer-reviewed publications. He has edited several books including the SITC-affiliated Cancer Immunotherapy
Principles and Practice Textbook.

 Dr.
Donald Banerji is a Clinical development professional with 33 years of global clinical research and development experience (Phase
I-IV) in the pharmaceutical industry. Recently retired from Novartis as Global Clinical Development Head of Respiratory and Allergy Medicine.
Recognized by peers and external scientific community as an expert in pulmonary and allergy drug development bringing several iconic
brands to market with millions of patients benefitting from treatment through improving care and outcomes for patients with respiratory
diseases. Managed multidisciplinary teams in the filing of several new drug applications. Responsibilities included strategic and tactical
planning, regulatory interactions with global health authorities, appropriate resource and budgetary management and timely execution,
approval of high-quality large drug development programs and delivery of groundbreaking data. These global programs over a span of 3
decades resulted in the approval and competitive labeling of 14 innovative medicines, including 3 inhaled steroids for asthma, a triple
combination of 2 bronchodilator and an inhaled steroid for asthma, 3 non-steroidal inhaled controller drugs for asthma, 3 intranasal
steroids for allergic rhinitis and 4 bronchodilator drugs for COPD. Signature achievements at Novartis included first to market with
the development and approval of the first to market inhaled dual combination medicine in COPD (Ultibro) and the first to market triple
combination medicine in asthma (Enerzair). With reimagining medicine as a core driver, these treatments changed the practice of medicine
and were incorporated in global treatment guidelines for COPD and asthma. Recipient of numerous corporate awards including the highest
scientific award of Distinguished Scientist 2016 for pioneering work in COPD. Published over 400 primary manuscripts and abstracts, including
the landmark study FLAME in NEJM.

 Dr.
Boris Minev is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic
viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development,
having worked closely on the development of the first cancer vaccine to be approved by a regulatory body (Melacine). Dr. Minev has also
extensive expertise in immunotherapy clinical trial designs, logistics, and regulatory issues. He has a considerable supervision &
management experience in industrial and academic settings and has excellent skills in biotech business development, communication, and
collaboration. Previously he held a position as the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where
he was directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy, and nanotechnology.

 Dr.
Minev is also an adjunct professor at the Moores UCSD Cancer Center. There, he served previously as Principal Investigator and Director,
Laboratory of Tumor Immunology and Immunotherapy where, for more than 15 years, his research has been focused on the discovery of new
target antigens for immunotherapy of cancer and the development of optimized cancer vaccines. Prior to that, Dr. Minev worked in Dr.
Steven Rosenberg's Tumor Immunology Section at the Surgery Branch of the National Cancer Institute.

 Dr.
Minev is an Advisory Board Member of the European Society for Translational Medicine (EUSTM). He is a member of the Scientific and Clinical
Advisory Boards of several biotechnology companies and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey
Consulting and Thomson Current Drugs, among others. He is the recipient of the European Association of Cancer Research Fellowship and
the Fogarty International Fellowship.

 Dr.
Pablo Guzman is a cardiologist in Fort Lauderdale, Florida where he is on staff at Holy Cross Hospital. He received his medical degree
from University of Puerto Rico School of Medicine and his Cardiology Fellowship at The Johns Hopkins Hospital where he then spent the
first part of his career continuing his basic science and clinical research along with his clinical duties. His CV includes over 25 papers
published in peer-reviewed journals and more than 15 abstracts.

 He
is a Fellow of the American College of Cardiology and practiced for more than 30 years. Dr. Guzman is well experienced in basic and clinical
research, having participated in many clinical trials. He is also the acting Chief Medical Officer of Variant Pharmaceuticals, a Specialty
Pharma company developing treatments for kidney diseases.

 Dr.
Juergen Winkler is presently practicing at Quantum Functional Medicine in Carlsbad, CA, which he founded in July of 2012. In 2005
he was the co-founder of Genesis Health Systems (Integrative Cancer and Medical Treatment Center) located in Oceanside, CA. He has been
a featured speaker for: the NSCC Women's Health Seminar, Annual IPT/IPTLD Integrative Cancer Care Conference (Multiple years),
Health Freedom Expo 2011 & 2012, the Japanese Society of Oxidative Medicine in Osaka Japan, ACOSPM 2010 & 2011 conferences, NSCC
Health and Wellness Series 2013, and various other events. He is the physician author of Chapter 5 in the Defeat Cancer book and has
been a featured physician in the Townsend Letter.

 Dr.
Nassir Azimi is a cardiologist in La Mesa, California and attended Dartmouth Medical School and completed his residency at the University
of Colorado. He finished his four year fellowship in Cardiovascular and Peripheral Interventions at Yale University in New Haven. Dr.
Azimi has been in private practice for over 13 years establishing a thriving clinical practice for cardiac patients as well as treating
patients for peripheral vascular disease. He is active in Interventional Cardiology and Peripheral Interventions. Dr. Azimi is the director
of La Mesa Cardiac Center's Nuclear Cardiology Laboratory. He is also an investigator in multiple clinical research studies for
various cardiac and peripheral diseases. He has been recognized as San Diego's Top Interventional Cardiologists by San Diego Magazine
2013,2014,2016, 2017 and also by Castle Connoly for 2013, 2014, 2015,2016, 2017, and 2018. He is a former chief of biomedical ethics
(6 years), former chief of Medicine and former chief of Endovascular Medicine as well as Vice Chief of Cardiology at SGH. He is on the
board of directors of the California ACC where he serves as chair of the public relations committee. He is on Editorial Review Board
for multiple medical journals. He is a national speaker on various topics in cardiology and internal medicine.

 Dr.
James Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University
School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency,
overseeing 36 doctors. Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014,
2016, and 2017) by his colleagues in the San Diego County Medical Society as a "Physician of Exceptional Excellence," the
most prestigious honor awarded to a "Top Doctor" in San Diego County. He is among a select group of San Diego physicians
who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently
the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

 Dr.
Barry Glassman, DMD, DAAPM, DAACP, FICCMO, Diplomate ABDSM, FADI, is a Diplomate of the American Academy of Craniofacial Pain and
the American Academy of Pain Management, as well as a Fellow of the International College of Craniomandibular Orthopedics and the Academy
of Dentistry International, he is also on staff at the Lehigh Valley Hospital where he serves as a resident instructor of Craniofacial
Pain and Dysfunction and Dental Sleep Medicine.

 Dr.
Glassman is a Diplomate of the Academy of Dental Sleep Medicine. He is on the staff at the Sacred Heart Hospital Sleep Disorder Center,
as well as serving as the Chief Dental Consultant to three other sleep centers in the Lehigh Valley. A popular and dynamic speaker, Dr.
Glassman lectures internationally, as well as throughout the United States. In addition to his extensive schedule which includes guest
lecture appearances and in-depth courses on joint dysfunction, chronic pain, headache, sleep disorders, and migraine headache, Dr. Glassman
is a frequent speaker at major chronic pain and joint dysfunction professional conferences. A graduate of the University of Pittsburgh:
Bachelor of Science 1969, Pittsburgh, Pennsylvania University of Pittsburgh School of Dental Medicine; D.M.D. 1973, Pittsburgh Pennsylvania
Post Graduate Hours in Craniomandibular Dysfunction and Sleep Disorders: Over 2500

 J.
Christopher Mizer founded Vivaris in June of 1998. Vivaris (formerly Lake Erie Capital) invests in and acquires middle-market businesses
in a broad range of industries that are leaders in their market niches. Mr. Mizer serves as the chairman of each of the portfolio companies
and guides key strategic decisions and their execution. He also serves as the operating president on an interim basis when companies
are going through periods of ownership succession and new management team members are being assembled.

 Mr.
Mizer is a former Vice President and Officer of the investment banking division of Key Capital Markets, where he focused on merger, acquisition,
and financing projects for Fortune 500 clients, private companies, and successful entrepreneurs. Prior to joining Key Corp., he was Consultant
in the Capital Markets practice with Ernst & Young. He began his career as a Research Assistant with The Center for Economic Issues,
a think-tank focused on economic development. He earned the B.S. (biology, applied math), B.A. (economics), M.S. degrees (biology –
neurogenetics), and MBA (finance, accounting) degrees from Case Western Reserve University. Mr. Mizer has taught business strategy, finance
and entrepreneurship at the graduate level at Case Western Reserve University, John Carroll University, and the University of California,
San Diego and at the undergraduate at San Diego State University.

 Howard
Leonhardt is an inventor and serial entrepreneur. He has 21 U.S. patents with over 100 patent claims for products for treating cardiovascular
disease and has over 40 new patent claims pending. His TALENT (Taheri-Leonhardt) stent graft developed in the early 1990 s holds
a leading world market share for repairing aortic aneurysms without surgery.

 His
inventions have treated over 500,000 patients in 60 countries. In early 1999 Leonhardt founded Bioheart, Inc. www.bioheartinc.com a leader
in applying adult muscle stem cells to treat heart failure.. Leonhardt holds a Diploma in International Trade from Anoka Technical College.
He attended the University of Minnesota, Anoka Ramsey College and UCLA Extension. He holds an honorary Doctorate in Biomedical Engineering
from the University of Northern California and is an honorary alumnus of the University of Florida and Florida International University.
He is co-leader of Startup California and Founder and Chairman of The California Stock Exchange TM (Cal-X) preparing to be the first
social good impact stock exchange currently operating the Cal-X 30 Social Good Impact fund powered by Motif Investing- www.calstockexchange.com
– He founded Cal-X Crowdfund Connect www.calxcrowdfund.com a crowdfunding campaign management co. and Cal-X Stars Business Accelerator,
Inc.www.calxstars.com a business incubator and accelerator focused on cardiovascular life sciences and social good impact innovations.

 There
are 30 regenerative medtech and regenerative economy startups in the current portfolio class. His Leonhardt Ventures angels network has
raised and put to work over $145 million in 32 companies to date, most of them founded by Leonhardt. BioLeonhardt www.bioleonhardt.com
is developing the first implantable programmable and re-fillable stem cell pump. He leads CerebraCell for brain regeneration. EyeCell
for eye regeneration and AortaCell for aorta regeneration and number of other organ regeneration spin offs from his patented core technologies.
Leonhardt serves as state spokesperson in California for the JOBS ACT and Crowdfunding for Startup California and has given over 40 speeches
on the subject. He has operated Leonhardt's Launchpads NorCal at the University of Northern California Science & Technology
Innovation Center in Rohnert Park, CA since 2008 and recently opened Leonhardt's Launchpads Utah in Salt Lake City just off the
campus of the University of Utah. He has served on the Board of Directors of the University of Northern California, a private biomedical
engineering school, since 1999.

 Section
16(a) Beneficial Ownership Reporting Compliance

 Section
16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class of our
equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other of
our equity securities. Officers, directors and greater than 10% stockholders are required by SEC regulation to furnish us with copies
of all Section 16(a) forms they file.

 To
our knowledge, based solely on a review of the copies of such reports furnished to us during the fiscal year ended December 31, 2023,
all Section 16(a) filing requirements applicable to our officers, directors and greater than 10% beneficial owners were complied with.

 Code
of Ethics

 We
have adopted a Code of Ethics for our principal executive and financial officers. Our Code of Ethics was filed as an Exhibit to our Annual
Report on Form 10-K for fiscal year 2010. We hereby undertake to provide a copy of this Code of Ethics to any person, without charge,
upon request. Requests for a copy of this Code of Ethics may be made in writing addressed to: Therapeutic Solutions International, Inc.,
4093 Oceanside Blvd, Suite B, Oceanside, California 92056, Attn: Corporate Secretary.

 ITEM

 EXECUTIVE
 COMPENSATION.

 Summary
Compensation Table

 The
following table summarizes the compensation paid, with respect to years ended December 31, 2023 and 2022 for services rendered to us
in all capacities, to each person who served as an executive officer of the Company.

 Name and Principal

 Salary

 Bonus

 Stock Awards

 Option Awards

 Nonequity Incentive Plan Compensation

 All Other Compensation

 Total

 Position

 Year

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 Timothy G. Dixon

 2023

 240,000
 (1)

 -

 125,000

 -

 -

 -

 365,000

 President, CEO and CFO

 2022

 240,000
 (2)

 -

 140,800

 -

 -

 -

 380,800

 Dr. James Veltmeyer

 2023

 -

 -

 75,000

 -

 -

 -

 75,000

 Chief Medical Officer

 2022

 -

 -

 -

 -

 -

 Feng Lin

 2023

 -

 -

 15,000

 -

 -

 -

 15,000

 Chief Scientific Officer

 2022

 -

 -

 -

 -

 -

 Famela Ramos

 2023

 -

 -

 15,100

 -

 -

 -

 15,000

 Vice President

 2022

 -

 -

 -

 -

 -

 (1)

 $120,000
 was accrued and $110,000 paid with stock as of December 31, 2023

 (2)

 $120,000
 was accrued and $67,400 paid with stock as of December 31, 2022

 Outstanding
Equity Awards

 None

 Employment
Agreements

 We
do not have any employment agreements as of December 31, 2023.

 Director
Compensation

 When
our employees serve on our Board of Directors, we do not give them any additional compensation in respect of such Board service. Directors
currently serve without compensation.

 ITEM

 SECURITY
 OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 The
following table sets forth, as of December 31, 2023, information regarding the ownership of the Company's outstanding shares of
common stock by (i) each person known to management to own, beneficially or of record, more than 5% of the outstanding shares of our
common stock, (ii) each director of the Company, (iii) each executive officer of the Company, and (iv) all directors and executive officers
as a group. As of December 31, 2023, a total of 3,802,666,978 shares of our common stock were outstanding.

 Name of Beneficial Owners

 Amount and Nature of Beneficial Ownership

 Percent of Shares Outstanding

 Timothy G. Dixon (1)

 358,993,103

 9.44
 %

 Thomas E. Ichim (1)

 142,000,000

 3.73
 %

 John Peck, Jr.

 227,283,333

 5.98
 %

 Feng Lin

 62,000,000

 1.63
 %

 James Veltmeyer

 37,000,000

 0.97
 %

 Famela Ramos

 6,000,000

 0.16
 %

 All directors and executive officers as a group (2 persons) (1)(2)

 500,953,103

 13.17
 %

 1)

 Under
 SEC rules (i) a person is deemed to be the beneficial owner of shares if that person has, either alone or with others, the power
 to vote or dispose of those shares. The persons named in the table have sole voting and dispositive power with respect to all shares
 shown as beneficially owned by them, subject to community property laws where applicable.

 ITEM

 CERTAIN
 RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 Our
Board of Directors currently consists of two directors, one of whom is an officer of the Company. As of December 31, 2023, we disclose
that we had no independent directors.

 In
general, it is our policy to submit all proposed related party transactions (those of the kind and size that may require disclosure under
Regulation S-K, Item 404) to the Board of Directors for approval. The Board of Directors only approves those transactions that are on
terms comparable to, or more beneficial to us than, those that could be obtained in arm's length dealings with an unrelated third
party. Examples of related party transactions covered by our policy are transactions in which any of the following individuals has or
will have a direct or indirect material interest: any of our directors or executive officers, any person who is known to us to be the
beneficial owner of more than 5% of our common stock, and any immediate family member of one of our directors or executive officers or
person known to us to be the beneficial owner of more than 5% of our common stock.

 ITEM

 PRINCIPAL
 ACCOUNTANT FEES AND SERVICES.

 Representatives
of our principal accountants, Fruci & Assoicates II, PLLC, will be available for the current year and for the most recently completed
fiscal year at the stockholder's meeting to provide the financial statements and be available for questions. At this time, we are
not planning to have a stockholder's meeting.

 Audit
Fees

 The
aggregate fees billed to us by our principal accountants, Fruci & Associates II, PLLC for auditing services for fiscal
year 2023 was $68,625 (inclusive of the review of the quarterly reports on Form 10-Q) and for year 2022 was $66,100.

 Audit-Related
Fees, Tax Fees and All Other Fees

 There
were no fees billed to us by our principal accountant for fiscal year 2023 and 2022 for assurance and related services (audit-related
fees), tax services or other products and services.

 Audit
Committee Matters

 We
do not have an audit committee. The executive officers and BOD perform the role of the audit committee. The executive officers and BOD
review and approve the audit. The audit fees were 100% and the audit related fees were 0% of the total fees and were approved by the
executive officers and BOD.

 PART
IV

 ITEM

 EXHIBITS
 AND FINANCIAL STATEMENT SCHEDULES

 a)
The following documents have been filed as a part of this Annual Report on Form 10-K

 1.

 Financial
 Statements

 Page

 Report of Independent Registered Public Accounting Firm (PCAOB ID # 5525)

 Consolidated Balance Sheets

 Consolidated Statements of Operations

 Consolidated Statement of Changes in Stockholders' Deficit

 Consolidated Statements of Cash Flows

 Consolidated Notes to Financial Statements

 2.

 Financial Statement Schedules.

 All
schedules are omitted because they are not applicable or not required or because the required information is included in the Financial
Statements or the Notes thereto.

 3.

 Exhibits.

 The
following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K:

 EXHIBIT

 NUMBER

 DESCRIPTION

 3.1

 Articles of Incorporation

 3.1.1

 Certificate of Merger, filed February 22, 2011

 3.1.2

 Certificate of Amendment to Articles of Incorporation filed October 15, 2012 (incorporated herein by reference to Form 8-K, filed on October 17, 2012)

 3.2

 Bylaws (incorporated herein by reference to Form SB-2, filed on November 21, 2007)

 3.2.1

 Bylaws
 amendments adopted August 22, 2012, August 24, 2012 and September 26, 2012 (incorporated herein by reference to Form 8-K, filed on October 17, 2012)

 31.1

 Rule 13a-14(a)/Section 302 Certification of Principal Executive Officer

 31.2

 Rule 13a-14(a)/Section 302 Certification of Principal Financial Officer

 32.1

 Certification pursuant to 18 U.S.C. Section 1350/Rule 13a-14(b)

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

 By:

 /s/
 Timothy G. Dixon

 Timothy
 G. Dixon

 Chief
 Executive Officer and President

 Date:

 April
 17, 2024

 By:

 /s/
 Thomas E. Ichim

 Thomas
 E. Ichim

 Director

 Date:

 April
 17, 2024

 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM

 To the Board of Directors and Shareholders of Therapeutic
Solutions International, Inc.

 Opinion on the Financial Statements

 We have audited the accompanying consolidated balance
sheets of Therapeutic Solutions International, Inc. and subsidiaries ("the Company") as of December 31, 2023 and 2022, and
the related consolidated statements of operations, changes in shareholders' deficit, and cash flows for each of the years in the
two-year period ended December 31, 2023, and the related notes (collectively referred to as the financial statements). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022
and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity
with accounting principles generally accepted in the United States of America.

 Going Concern

 The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred
significant losses since inception, has not generated material revenue from operations and requires additional funds to maintain its operations.
This factor, among others, raise substantial doubt about the Company's ability to continue as a going concern. Management's
plans in regard to this matter are also described in Note 1. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control over financial reporting. Accordingly, we express no such opinion.

 Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 Critical Audit Matters

 Critical audit matters are matters arising from the
current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that
(1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective,
or complex judgments. We determined that there were no critical audit matters.

 Fruci
& Associates II, PLLC – PCAOB ID #05525

 We
have served as the Company's auditor since 2019.

 Spokane,
Washington

 April
17, 2024

 F- 1

 Balance Sheets

 December 31,
2023

 December 31,
2022 (Restated)

 ASSETS

 Current assets:

 Cash and cash equivalents

 $
 27,823

 $
 18,434

 Restricted cash

 -

 11,003

 Accounts receivable

 19,196

 25,398

 Inventory

 22,574

 42,428

 Prepaid expenses and other current assets

 16,320

 212,352

 Total current assets

 85,913

 309,615

 Property and equipment, net

 374,355

 273,078

 Right-of-use asset

 125,557

 8,612

 Other assets

 2,706,187

 3,014,620

 Total assets

 $
 3,292,012

 $
 3,605,925

 LIABILITIES AND SHAREHOLDERS' EQUITY

 Current liabilities:

 Accounts payable

 $
 397,674

 $
 399,410

 Accounts payable-related parties

 7,204

 9,791

 Accounts payable

 $
 397,674

 $
 399,410

 Accrued expenses and other current liabilities

 536,118

 531,783

 Lease liability

 20,525

 8,612

 Notes payable, current portion

 4,638

 4,638

 Convertible notes payable, net of discount of $ 112,384 and $ 175,063, at December 31, 2023 and 2022, respectively

 49,616

 65,187

 Notes payable-related parties, net

 702,741

 988,672

 Derivative liabilities

 181,070

 202,144

 Total current liabilities

 1,899,586

 2,210,237

 LONG TERM LIABILITIES

 Notes payable, net of current portion

 5,512

 10,507

 Lease liability, net of current portion

 105,032

 -

 TOTAL LIABILITIES

 2,010,130

 2,220,744

 Commitments and contingencies

 -

 -

 Shareholders' Equity:

 Preferred stock, $ 0.001 par value; 5,000,000 shares authorized, 2 shares and 2 shares issued and outstanding at December 31, 2023 and 2022, respectively

 -

 -

 Common stock, $ 0.001 par value; 5,500,000,000 and 3,500,000,000 shares authorized, respectively; 3,802,666,978 and 2,617,390,830 shares issued and outstanding at December 31, 2023 and 2022, respectively.

 3,802,668

 2,617,392

 Additional paid-in capital

 17,670,092

 16,655,643

 Shares to be issued

 -

 126,324

 Subscription receivable

)

)

 Accumulated deficit

 ( 20,326,465
)

 ( 18,156,651
)

 Total shareholders' equity

 1,125,295

 1,221,708

 Non-controlling interest

 156,587

 163,473

 Total shareholders' equity - Therapeutic Solutions International, Inc.

 1,281,882

 1,385,181

 Total liabilities and shareholders' equity

 $
 3,292,012

 $
 3,605,925

 See
accompanying notes to consolidated financial statements.

 F- 2

 Consolidated Statements of Operations

 For the Year Ended December 31, 2023

 For
 the Year Ended December 31, 2022 (Restated)

 Net sales

 $
 98,994

 $
 206,767

 Cost of goods sold

 36,768

 79,440

 Gross profit

 62,226

 127,327

 Operating expenses:

 General and administrative

 474,960

 497,151

 Salaries, wages, and related costs

 433,324

 444,865

 Consulting fees

 148,570

 612,658

 Legal and professional fees

 431,197

 399,902

 Research and development

 560,654

 1,452,128

 Total operating expenses

 2,048,705

 3,406,704

 Loss from operations

 ( 1,986,479
)

 ( 3,279,377
)

 Other income (expense):

 Gain (loss) on derivative liabilities

 36,985

 ( 131,475
)

 Change in fair value of derivative liabilities

 ( 17,836
)

 291,123

 Interest expense

 ( 423,265
)

 ( 646,089
)

 Gain on extinguishment of debt

 168,145

 -

 Other expense

 -

 ( 110,642
)

 Total other income (expense)

 ( 235,971
)

 ( 597,083
)

 Loss before provision for income taxes

 ( 2,222,450
)

 ( 3,876,460
)

 Provision for income taxes

 2,250

 1,600

 Net loss before non-controlling interest

 ( 2,224,700
)

 ( 3,878,060
)

 Loss attributable to non-controlling interest

 ( 54,886
)

 ( 64,079
)

 Net loss attributable to Therapeutic Solutions International, Inc.

 $
 ( 2,169,814
)

 $
 ( 3,813,981
)

 Net loss per share - basic and diluted

 $
 ( 0.00
)

 $
 ( 0.00
)

 Weighted average shares outstanding - basic and diluted

 3,168,900,801

 2,528,062,958

 See
accompanying notes to consolidated financial statements.

 F- 3

 Consolidated Statements of Changes in Shareholders'
Deficit

 For the
Years Ended December 31, 2023 and 2022

 Series A Preferred Stock

 Common Stock

 Additional

 Paid-in

 Shares to

 Subscription

 Accumulated

 Non-controlling

 Total
Shareholders'

 Equity

 Shares

 Amount

 Shares

 Amount

 Capital

 be Issued

 Receivable

 Deficit

 Interest

 (Deficit)

 December 31, 2021

 -

 $
 -

 2,311,123,860

 $
 2,311,125

 $
 11,220,653

 $
 -

 $
)

 $
 ( 14,342,670
)

 $
 227,552

 $
 ( 604,340
)

 Common stock issued for services

 -

 -

 32,412,577

 32,413

 557,107

 102,000

 -

 -

 -

 691,520

 Common stock issued for prepaid fees

 -

 -

 11,000,000

 11,000

 231,320

 -

 -

 -

 -

 242,320

 Common stock issued for salaries

 -

 -

 4,812,259

 4,812

 62,587

 -

 -

 -

 -

 67,399

 Common stock issued for cash

 -

 -

 44,500,000

 44,500

 400,500

 -

 -

 -

 -

 445,000

 Common stock issued for license

 -

 -

 149,402,390

 149,402

 2,958,168

 -

 -

 -

 -

 3,107,570

 Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities

 -

 -

 64,139,744

 64,140

 1,225,308

 24,324

 -

 -

 -

 1,313,772

 Issuance of preferred stock

 -

 -

 -

 -

 -

 -

 -

 -

 -

 Net loss

 -

 -

 -

 -

 -

 -

 -

 ( 3,813,981
)

 ( 64,079
)

 ( 3,878,060
)

 $
 -

 2,617,390,830

 $
 2,617,392

 $
 16,655,643

 $
 126,324

 $
)

 $
 ( 18,156,651
)

 $
 163,473

 $
 1,385,181

 Balance

 $
 -

 2,617,390,830

 $
 2,617,392

 $
 16,655,643

 $
 126,324

 $
)

 $
 ( 18,156,651
)

 $
 163,473

 $
 1,385,181

 Common stock issued for services

 -

 -

 115,257,394

 115,257

 163,654

 ( 102,000
)

 -

 -

 -

 176,911

 Common stock issued for salaries

 -

 -

 64,081,632

 64,082

 45,918

 -

 -

 -

 -

 110,000

 Common stock issued for cash

 -

 -

 556,632,297

 556,632

 233,800

 -

 -

 -

 -

 790,432

 Common stock issued by subsidiary for services

 -

 -

 -

 -

 53,841

 -

 -

 -

 48,000

 101,841

 Common stock issued for land development

 -

 -

 60,000,000

 60,000

 36,000

 -

 -

 -

 -

 96,000

 Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities

 -

 -

 389,304,825

 389,305

 481,236

 ( 24,324
)

 -

 -

 -

 846,217

 Net loss

 -

 -

 -

 -

 -

 -

 -

 ( 2,169,814
)

 ( 54,886
)

 ( 2,224,700
)

 $
 -

 3,802,666,978

 $
 3,802,668

 $
 17,670,092

 $
 -

 $
)

 $
 ( 20,326,465
)

 $
 156,587

 $
 1,281,882

 Balance

 $
 -

 3,802,666,978

 $
 3,802,668

 $
 17,670,092

 $
 -

 $
)

 $
 ( 20,326,465
)

 $
 156,587

 $
 1,281,882

 See
accompanying notes to consolidated financial statements.

 F- 4

 Consolidated Statements of Cash Flows

 For the Year Ended December 31, 2023

 For
 the Year Ended December 31, 2022 (Restated)

 Cash flows from operating activities

 Net loss

 $
 ( 2,224,700
)

 $
 ( 3,878,060
)

 Adjustments to reconcile net loss to net cash used in operating activities:

 Stock-based compensation to consultants

 101,841

 380,820

 Stock-based compensation to related parties

 176,911

 310,700

 Loss on derivative liabilities

 ( 36,985
)

 131,475

 Change in fair value of derivative liabilities

 17,836

 ( 291,123
)

 Gain on extinguishment of debt

 ( 168,145
)

 -

 Amortization of prepaid stock-based compensation

 116,793

 951,748

 Amortization of debt discount

 384,744

 593,463

 Patent amortization

 300,897

 233,685

 Depreciation

 10,881

 10,946

 Changes in operating assets and liabilities:

 Accounts receivable

 6,202

 ( 8,785
)

 Inventory

 19,854

 ( 2,611
)

 Prepaid expenses and other current assets

 94,618

 354,989

 Right-of-use asset

 29,299

 25,572

 Accounts payable

 ( 1,738
)

 15,166

 Accounts payable - related parties

 ( 2,587
)

 ( 9,791
)

 Accrued expenses and other current liabilities

 148,288

 169,451

 Lease liability

 ( 29,299
)

 ( 25,572
)

 Net cash used in operating activities

 ( 1,055,290
)

 ( 1,037,927
)

 CASH FLOWS FROM INVESTING ACTIVITIES:

 Purchases of property and equipment

 ( 16,158
)

 -

 Purchase of license

 -

 -

 Issuance of note receivable

 ( 7,842
)

 -

 Net cash used in investing activities

 ( 24,000
)

 -

 Cash flows from financing activities

 Payments on notes payable to related party

 ( 21
)

 ( 2,453
)

 Proceeds from notes payable to related party

 6,510

 -

 Proceeds from convertible notes payable

 285,750

 505,000

 Payments on notes payable

 ( 4,995
)

 ( 4,459
)

 Proceeds from sale of common stock

 790,432

 445,000

 Net cash provided by financing activities

 1,077,676

 943,088

 Net decrease in cash, cash equivalents and restricted cash

 ( 1,614
)

 ( 94,839
)

 Cash, cash equivalents and restricted cash at beginning of period

 29,437

 124,276

 Cash, cash equivalents and restricted cash at end of period

 $
 27,823

 $
 29,437

 Supplemental cash flow information:

 Cash paid for interest

 $
 2,761

 $
 3,173

 Cash paid for income taxes

 $
 1,450

 $

 Non-cash investing and financing transactions:

 Original issuance discount on convertible notes payable

 $
 37,500

 $
 39,000

 Debt discount recorded in connection with derivative liability

 $
 284,565

 $
 503,726

 Common stock issued in conversion of convertible notes payable and interest

 $
 846,217

 $
 1,313,772

 Common stock issued for prepaid fees

 $
 -

 $
 242,320

 Common stock issued for accrued salaries

 $
 110,000

 $
 67,399

 Accrued interest added to principal

 $
 13,126

 $
 25,914

 Common stock issued for license

 $
 -

 $
 3,107,570

 Common stock issued for land development

 $
 96,000

 $
 50,400

 Right of use asset and lease liability

 $
 146,244

 $
 -

 Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:

 Cash and cash equivalents

 $
 27,823

 $
 18,434

 Restricted cash

 -

 11,003

 Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows:

 $
 27,823

 $
 29,437

 See
accompanying notes to consolidated financial statements.

 F- 5

 NOTES

 Note
1 – Organization and Business Description

 Therapeutic
Solutions International, Inc. ("TSOI" or the "Company") was organized August 6, 2007, under the name Friendly
Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto
Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.

 Business
Description

 Currently
the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to
upregulate (make more active) or downregulate (make less active) one's immune system.

 Activating
one's immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections
and to prevent illness. Additionally, inhibiting one's immune system is vital for reducing inflammation, autoimmune disorders and
allergic reactions.

 TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
and for daily health.

 Nutraceutical
Division – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune, is a multi-patented
synergistic blend of pterostilbene, sulforaphane, epigallocatechin-3-gallate, and thymoquinone. QuadraMune has been shown to increase
Natural Killer Cell activity and healthy Cytokine production.

 Regenerative
Medicine – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

 The
stem cell licensed, termed "JadiCell" is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal
like stromal cells.

 Immunotherapies

 TSOI
has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to parkinson's disease developed on
our StemVacs platform.

 F- 6

 NOTES

 Management
does not expect existing cash as of December 31, 2023, to be sufficient to fund the Company's operations for at least twelve months
from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed
the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2023,
the Company has incurred losses totaling $ 20.1 million since inception, has not yet generated material revenue from operations, and will
require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company's ability to continue
as a going concern within one year after the consolidated financial statements are issued. The Company's ability to continue as
a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its
obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating
costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings,
debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required
to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments
to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the
Company be unable to continue as a going concern.

 Note
2 – Basis of presentation and significant accounting policies

 Basis
of Presentation

 The
consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles
("U.S. GAAP"). In the opinion of the Company's management, the consolidated financial statements include all adjustments,
which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial position for the
periods presented.

 Principles
of Consolidation

 The
accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc., its wholly owned subsidiaries,its
 68 %
 owned subsidiary Res Nova Bio, Inc. and its 52 %
 owned subsidiary Campbell Neurosciences, Inc.
All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.
 The Company reinstated the 2022 Financial Statements due to the evaluation of Campbell Neurosciences as a variable interest entity
(VIE), having a controlling interest despite not having voting rights. The Company didn't appropriately identify and consolidate
the VIE.

 Accounts
Receivable

 On
January 1, 2023, the Company adopted ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses
on Financial Instruments (ASC 326). This standard replaced the incurred loss methodology with an expected loss methodology that is referred
to as the current expected credit loss ("CECL") methodology. CECL requires an estimate of credit losses for the remaining
estimated life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally
applies to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance
sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at
the net amount expected to be collected by using an 2 allowance for credit losses.

 The
company looks at historical losses, assesses current and future events to adjust historical information as necessary, and applies percentages
to accounts receivable balances based on aging.

 The
company recorded an allowance for doubtful accounts of $ 6,807 as of both December 31, 2023 and 2022, respectively.

 Revenue
Recognition

 The
Company recognizes revenue in accordance with ASC 606, "Revenue from Contracts with Customers" ("ASC 606"). In
accordance with ASC 606, the Company applies the following methodology to recognize revenue:

 1)

 Identify the contract with
 a customer.

 2)

 Identify the performance
 obligations in the contract.

 3)

 Determine the transaction
 price.

 4)

 Allocate the transaction
 price to the performance obligations in the contract.

 5)

 Recognize revenue when
 (or as) the entity satisfies a performance obligation.

 ASC
606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount
that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally
satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which
the customer obtains control of the product or service.

 The sales were $ 98,994 and $ 206,767 as of December 31, 2023, and 2022, respectively.

 Returns.
 Revenue is adjusted based on an estimate of the expected returns based on historical rates. Our
estimate of the provision for returns is based upon our most recent historical experience of actual customer returns. Additionally, we
consider other factors when estimating our current period return provision, including levels of inventory in our distribution channel
as well as significant market changes which may impact future expected returns, and make adjustments to our current period provision
for returns when it appears product returns may differ from our original estimates. These returns have not been significant to the Company's
revenues in the accompanying financial statements.

 Wholesale
policies:

 Delivery.
 The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall
be determined by Seller, but Buyer will not be responsible for shipping costs.

 Purchase
Price & Payments. Seller
agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price. Seller will provide an invoice to Buyer
at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days
will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of
aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%)
discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products
having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the
aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off
retail.

 F- 7

 NOTES

 Inspection
of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer
must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods
within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods.
In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall
be determined by industry standards for the particular Goods, as well as the Seller and Buyer.

 Risk
of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary
insurance in order to insure the Goods against loss at Seller's own expense

 Retail
policies of e-commerce:

 Shipping.
 Shipping Time — Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed
or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or
transit time offered to the customer by this site or other parties only as an estimate. We encourage the customer to order in a timely
fashion to avoid delays caused by shipping or product availability. Fulfillment mistakes that may be made which result in the shipment
of incorrect products to the customer will also be accepted for return.

 Out
of Stock. We will ship the customer's product as it becomes available. Usually, products ship by the next business day. However,
there may be times when the product the customer had ordered is out-of-stock, which will delay fulfilling the customer's order.
We will keep the customer informed of any products that the customer had ordered that are out-of-stock and unavailable for immediate
shipment. The Customer may cancel their order at any time prior to shipping.

 Cash
and Cash Equivalents

 The
Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

 Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each
institution are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $ 250,000. At December 31, 2023 and 2022,
the Company had $ 0 in excess of the FDIC insured limit.

 Inventories

 Inventories
are stated at lower of cost (using the first-in, first-out method, "FIFO") or market. Inventories consist of purchased materials
and assembly items.

 Derivative
Liabilities

 A
derivative is an instrument whose value is "derived" from an underlying instrument or index such as a future, forward, swap,
option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other
contracts and for hedging activities.

 As
a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company
entered into certain debt financing transactions in fiscal 2023 and 2022, as disclosed in Note 7 containing certain conversion features
that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments
within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out
basis.

 The
classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during
a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on
the number of times a contract may be reclassified.

 F- 8

 NOTES

 Instruments
classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification)
and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 181,070
and $ 202,144 at December 31, 2023 and 2022, respectively.

 Fair
Value of Financial Instruments

 The
Company's financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount
of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

 Fair
value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed
by level within the following fair value hierarchy:

 Level
1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

 Level
2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability
through correlation with market data at the measurement date and for the duration of the instrument's anticipated life.

 Level
3 – Inputs lack observable market data to corroborate management's estimate of what market participants would use in pricing
the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent
in the inputs to the model.

 When
determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable
market data is not available. As of December 31, 2023 and 2022, the Company has level 3 fair value calculations on derivative liabilities.

 The
following is the change in derivative liability for the years ended December 31, 2023 and 2022:

 Schedule
of Change in Derivative Liability

 Balance, December 31, 2021

 $
 531,525

 Issuance of new derivative liabilities

 674,971

 Conversions

 ( 713,229
)

 Change in fair market value of derivative liabilities

 ( 291,123
)

 Balance, December 31, 2022

 202,144

 Issuance of new derivative liabilities

 371,761

 Conversions

 ( 410,671
)

 Change in fair market value of derivative liabilities

 17,836

 Balance, December 31, 2023

 $
 181,070

 Use
of Estimates

 Estimates
were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could
differ materially from those estimates.

 Comprehensive
Loss

 Comprehensive
loss for the periods reported was comprised solely of the Company's net loss.

 Non-Controlling
Interests

 Non-controlling
interests disclosed within the consolidated statement of operations represent the minority ownership's 68 % share of net losses
of Res Nova Bio, Inc. and 52 % share of net losses of Campbell Neurosciences, Inc. incurred during the year ended December 31, 2023.

 Net
Loss Per Share

 Basic
loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding
during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased
to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such
additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the
same, and additional potential common shares have been excluded as their effect would be antidilutive.

 As
of December 31, 2023, and 2022, a total of 1,151,186,465 and 267,136,056, respectively,
potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would
be antidilutive.

 F- 9

 NOTES

 Depreciation
and Amortization

 Depreciation
is calculated using the straight-line method over the estimated useful lives of the assets. Amortization is computed using the straight-line
method over the term of the agreement. Depreciation expense for the year ended December 31, 2023, and 2022 was $ 10,881 and $ 10,946, respectively.

 Intangible
Assets

 Intangible
assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized
in accordance with ASC Topic 350 "Intangibles – Goodwill and Other." Intangible assets with finite lives are amortized
over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the
carrying amount may not be recoverable. Amortization expense for the year ended December 31, 2023, and 2022 was $ 300,897 and $ 233,685,
respectively.

 Long-lived
Assets

 In
accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed
on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the
sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured
as the excess of the carrying amount of the asset over its estimated fair value.

 Shipping
and Handling

 The
Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within
the general administrative expenses.

 Advertising

 Advertising
costs are expensed as incurred. Advertising expense for the years ended December 31, 2023 and 2022 were $ 3,549 and $ 4,132, respectively.

 Research
and Development

 Research
and Development costs are expensed as incurred. Research and Development expenses were $ 560,654 and $ 1,452,128 for the year ended December
31, 2023, and 2022, respectively.

 Income
Taxes

 The
Company accounts for income taxes under ASC 740 "Income Taxes," which codified SFAS 109, "Accounting for
Income Taxes" and FIN 48 "Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No.
109." Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their
respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided
for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 Stock-Based
Compensation

 Compensation
expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the
equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to
expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for
fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective
date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was
no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted
and nonrefundable shares.

 Leases

 On
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance
sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02
became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases
existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company
recorded a Right-of-use asset and a Lease Liability of $ 125,557 as of December 31, 2023.

 F- 10

 NOTES

 Recently
Issued Accounting Pronouncements

 In
August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts
in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity
("ASU 2020-06"). This update simplifies the accounting for certain convertible instruments by removing the separation models
for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result,
more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion
features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use
of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using
either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller
reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those
fiscal years. The accounting guidance has been adopted with no significant financial statement impact.

 Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company's financial statement presentation or disclosures.

 Note
3 – Balance Sheet Reinstatement

 The Company's subsidiary, on various dates in
2021, issued stock to various founders and investors. The stock has been fluctuating and the percentage of stock ownership by the company
varied. The Company reinstated the 2022 Financial Statements due to the evaluation of the subsidiary as a variable interest entity (VIE),
having a controlling interest despite not having voting rights. The Company didn't appropriately identify and consolidate the VIE.
The Company has issued additional shares which brings the ownership of the subsidiary over 50%, management determined that they should
be included in the financial statements. The balance sheet as of December 31, 2022, has therefore been restated, with the accounts impacted
by the change detailed below:

 Schedule
of Balance Sheet Reinstatement

 Originally

 Reported

 As Restated

 Change

 Cash and cash equivalents

 $
 18,040

 $
 18,434

 $
 ( 394
)

 Total assets

 $
 3,605,531

 $
 3,605,925

 $
 ( 394
)

 Additional paid-in capital

 $
 16,334,129

 $
 16,655,643

 $
 ( 321,514

)

 Accumulated deficit

 ( 17,672,058
)

 ( 18,156,651
)

 484,593

 Total shareholders' equity

 1,384,787

 1,221,708

 163,079

 Non-controlling interest

 -

 163,473

 ( 163,473
)

 Total liabilities and stockholders' equity

 $
 3,605,531

 $
 3,605,925

 $
 ( 394
)

 Originally Reported

 As Restated

 Change

 General and administrative

 $
 491,928

 $
 497,151

 $
 ( 5,223
)

 Consulting fees

 432,033

 612,658

 ( 180,625
)

 Legal and professional fees

 397,302

 399,902

 ( 2,600
)

 Research and development

 1,441,128

 1,452,128

 ( 11,000
)

 Loss from operations

 ( 3,079,929
)

 ( 3,279,377
)

 199,448

 Loss before provision for income taxes

 ( 3,677,012
)

 ( 3,876,460
)

 199,448

 Provision for income taxes

 1,600

 ( 800
)

 Net loss before non-controlling interest

 ( 3,677,812
)

 ( 3,878,060
)

 200,248

 Loss attributable to non-controlling interest

 -

 ( 64,079
)

 64,079

 Net loss attributable to Therapeutic Solutions International, Inc.

 $
 ( 3,677,812
)

 $
 ( 3,942,139
)

 $
 264,327

 Note
4 – Prepaid expense and other current assets

 Prepaid
expenses and other current assets consist of the following:

 Schedule of Prepaid Expenses and Other Current Assets

 Prepaid consulting

 $
 11,037

 $
 148,550

 Insurance

 1,167

 1,141

 Prepaid costs and other

 4,116

 62,661

 Total

 $
 16,320

 $
 212,352

 F- 11

 NOTES

 Note
5 – Fixed assets

 Fixed
assets consist of the following:

 Schedule of Fixed Assets

 Land

 $
 347,381

 $
 235,223

 Vehicles

 50,514

 50,514

 Computer hardware

 6,135

 6,135

 Office furniture and equipment

 7,912

 7,912

 Shipping and other equipment

 1,575

 1,575

 Total

 413,517

 301,359

 Accumulated depreciation

 ( 39,162
)

 ( 28,281
)

 Property and equipment, net

 $
 374,355

 $
 273,078

 Depreciation
expense was $ 10,881 and $ 10,946 for the years ended December 31, 2023, and 2022, respectively.

 Note
6 – Other assets

 Other
assets consist of the following:

 Schedule of Other Assets

 Prepaid consulting

 $
 -

 $
 7,537

 Deposit

 4,123

 4,123

 Licenses, net

 2,702,064

 3,002,960

 Total

 $
 2,706,187

 $
 3,014,620

 As
of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December
31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy),
and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived
from US Patent No.: 9,803,176 B2.

 F- 12

 NOTES

 Prepaid
consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above
consists of the following:

 Schedule of Net Licenses

 License

 $
 3,261,122

 $
 3,261,122

 Accumulated amortization

 ( 559,058
)

 ( 258,162
)

 Licenses, net

 $
 2,702,064

 $
 3,002,960

 Amortization
expense for the years ended December 31, 2023 and 2022 was $ 300,897 and $ 233,685, respectively.

 Note
7 - Notes Payable-Related Party

 Notes
payable-related parties consist of:

 Schedule
of Notes Payable Related Parties

 6,510

 -

 Various notes payable – Board of Directors Member, unsecured, including interest at
 10 % per annum, with maturity dates ranging from January 2024 to November 2024

 $
 6,510

 $
 -

 Three notes payable – Chief Executive Officer, unsecured, including interest at 8 %, 10 % and 10 %
 per annum, respectively, with maturity date of December 31, 2019

 30,604

 29,090

 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of
 revenues

 534,427

 534,448

 Note payable – Chief Financial Officer, unsecured, including interest at 8 % per annum, with a
 maturity date of December 31, 2019

 131,200

 124,800

 Three notes payable – Business Advisory Board Member, unsecured, including
 interest at 8 % and 10 % per annum, convertible into common stock at $ 0.005 and $ 0.004, respectively, with maturity date of April 20,
 2019

 -

 300,334

 $
 702,741

 $
 988,672

 At
December 31, 2023 and 2022, the Company has unsecured interest-bearing demand notes outstanding to certain officers and directors
amounting to $ 702,741
and $ 988,672
respectively. Interest accrued on these notes during the year ended December 31, 2023, and 2022 was $ 14,631
and $ 25,913,
respectively. The notes payable with a maturity date of December 31, 2019, are in default.

 Note
8 – Convertible Notes Payable

 At
various times during the years ended December 31, 2023 and 2022, the Company entered into convertible promissory notes with principal
amounts totaling $ 323,250 and $ 544,000, respectively, with a third party for which the proceeds were used for operations. The Company
received net proceeds of $ 285,750 and $ 505,000, respectively, and a $ 37,500 and $ 39,000 original issuance discount was recorded, respectively.
The convertible promissory notes incur interest at 10 % per annum and mature on dates ranging from January 2023 to November 2024. The
convertible promissory notes are convertible to shares of the Company's common stock 180 days after issuance. The conversion price
per share is equal to 63% of the average of the three (3) lowest trading prices of the Company's common stock during the fifteen
(15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing
bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing
subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment.
The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with
the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at December 31, 2023 a total of
 1,151,186,465 common shares in connection with these promissory notes.

 Derivative
liabilities

 These
convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number
of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented
an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability
is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes
in the derivative liability fair value are reported in operating results each reporting period.

 For
the notes issued during the year ended December 31, 2023, the Company valued the conversion feature on the date of issuance resulting
in an initial liability of $ 371,761. Since the fair value of the derivative was in excess of the proceeds received, a full discount to
convertible notes payable and a day one loss on derivative liabilities of $ 87,196 was recorded during the year ended December 31, 2023.
Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions:
conversion prices ranging from $ 0.0008 to $ 0.0034, the closing stock price of the Company's common stock on the date of valuation
ranging from $ 0.0011 to $ 0.006, an expected dividend yield of 0 %, expected volatility ranging from 124 % to 161 %, risk-free interest rate
ranging from 4.67 % to 5.46 %, and an expected term of one year.

 F- 13

 NOTES

the year ended December 31, 2023, convertible notes with principal and accrued interest balances totaling $ 418,363 were converted into
 331,554,825 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated
with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the fair value of
the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative liability as compared to the portion
of the convertible note converted was recorded as a loss or gain on derivative liabilities. During the year ended December 31, 2023,
the Company recorded $ 124,181 to gain on derivative liabilities in connection with these conversions. The derivative liabilities were
revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $ 0.0007 to $ 0.004,
the closing stock price of the Company's common stock on the date of valuation ranging from $ 0.001 to $ 0.006, an expected dividend
yield of 0 %, expected volatility ranging from 110 % to 193 %, risk-free interest rates ranging from 4.55 % to 5.41 %, and expected terms
of 0.46 to 0.50 years.

 On
December 31, 2023, the derivative liabilities on the remaining convertible notes were revalued at $ 181,070 resulting in a loss of $ 17,836
for the year ended December 31, 2023, related to the change in fair value of the derivative liabilities. The derivative liabilities were
revalued using the Black-Scholes option pricing model with the following assumptions: exercise prices of $ 0.0006, the closing stock price
of the Company's common stock on the date of valuation of $ 0.001, an expected dividend yield of 0 %, expected volatility ranging
from 135 % to 153 %, risk-free interest rate of 4.79 %, and an expected term ranging from 0.55 to 0.84 years.

 For
the notes issued during the year ended December 31, 2022, the Company valued the conversion features on the date of issuance resulting
in initial liabilities totaling $ 674,971. Since the fair value of the derivative was in excess of the proceeds received, a full discount
to convertible notes payable and a day one loss on derivative liabilities of $ 171,245 was recorded during the year ended December 31,
2022. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion
prices ranging from $ 0.0058 to $ 0.0143, the closing stock price of the Company's common stock on the dates of valuation ranging
from $ 0.008 to $ 0.0272, an expected dividend yield of 0 %, expected volatilities ranging from 148 %- 216 %, risk-free interest rate ranging
from 0.48 % to 4.77 %, and an expected term of one year.

the year ended December 31, 2022, convertible notes principal plus their accrued interest totaling $ 774,176 were converted into 68,193,798
shares of common stock, of which 4,054,054 were yet to be issued as of December 31, 2022. At each conversion date, the Company recalculated
the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair
market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative
liability as compared to the portion of the convertible note converted was recorded as a loss or gain on derivative liabilities. During
the year ended December 31, 2022, the Company recorded $ 39,770 to gain on derivative liabilities. The derivative liabilities were revalued
using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $ 0.0038 to $ 0.016, the closing
stock price of the Company's common stock on the dates of valuation ranging from $ 0.006 to $ 0.026, an expected dividend yield of
 0 %, expected volatility ranging from 63 % to 191 %, risk-free interest rates ranging from 0.51 % to 4.74 %, and expected terms ranging from
 0.44 to 0.50 years.

 On
December 31, 2022, the derivative liabilities on the remaining convertible notes were revalued at $ 202,144 resulting in a gain of $ 291,123
for the year ended December 31, 2022 related to the change in fair value of the derivative liabilities. The derivative liabilities were
revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $ 0.0038, the closing stock price
of the Company's common stock on the date of valuation of $ 0.006, an expected dividend yield of 0 %, expected volatility ranging
from 96 % to 120 %, risk-free interest rate of 4.71 %, and an expected term ranging from 0.49 to 0.93 years.

 The
Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to
the effective interest method. During the years ended December 31, 2023, and 2022, the Company amortized $ 384,744 and $ 593,463 to interest
expense, respectively. As of December 31, 2023, discounts of $ 112,384 remained which will be amortized through November 2024.

 Note
9 – Related party transactions

 As
of December 31, 2019 and 2018, the Company had accrued officers' salary of $ 439,534 and $ 663,100, respectively. One of the officers
settled with the company for a note payable that is unsecured on November 8, 2019 and doesn't accrue interest and will be paid
as 0.5 % of revenues. This decreased accrued officers' salary. The note is still outstanding as of December 31, 2023 and 2022. Payments
for the years ended December 31, 2023 and 2022 was $ 21 and $ 97, respectively.

 In
2022, we issued 4,812,259 shares of common stock for $ 67,399 of accrued salaries to one officer of the Company under a Restricted Stock
Award.

 On
April 5, 2022, we issued 7,000,000 shares of common stock, to four officers and one director of the Company under a Restricted Stock
Award for $ 175,700.

 On
September 8, 2022, we issued 4,000,000 shares of common stock to one officer and one director under a Restricted Stock Award for $ 46,400.

 On
November 2, 2022, we issued 3,000,000 shares of common stock to one director under a Restricted Stock Award for $ 29,700.

 On
December 30, 2022, we committed to issue 14,000,000 shares of common stock, to four officers and one director of the Company under a
Restricted Stock Award for $ 84,000, which were subsequently issued on January 3, 2023.

 On
January 9, 2023, we issued 4,081,632 shares of common stock, for accrued salaries to one officer of the Company under a Restricted Stock
Award for $ 20,000.

 On
January 9, 2023, we issued 4,000,000 shares of common stock to one director under a Restricted Stock Award for $ 19,600.

 On
April 20, 2023, we issued 25,000,000 shares of common stock, to one officer of the Company under a Restricted Stock Award for $ 60,000.

 On
May 10, 2023, we issued 57,750,000 shares of common stock for the conversion of convertible notes of $ 220,000 under a Restricted Stock
Award.

 On
October 16, 2023, we issued 60,000,000 shares of common stock, for accrued salaries to one officer of the Company under a Restricted
Stock Award for $ 90,000.

 On
October 16, 2023, we issued 50,000,000 shares of common stock, to three officers and one director of the Company under a Restricted Stock
Award for $ 70,000.

 F- 14

 NOTES

 Note
10 – Income taxes

 The
Company is subject to United States federal and state income taxes at an approximate rate of 30 %. The reconciliation of the provision
for income taxes at the United States federal statutory rate compared to the Company's income tax expense as reported is as follows:

 Schedule of Income tax Expense

 Expected income tax at statutory rate

 $
 ( 562,532
)

 $
 ( 709,666
)

 State tax

 ( 123,226
)

 ( 101,347
)

 Permanent differences

 193,901

 405,376

 Other

 -

 -

 Change in valuation allowance

 494,107

 407,237

 Provision for income taxes

 $
 2,250

 $
 1,600

 The
significant components of deferred income tax assets and liabilities at December 31, 2023 and 2022 are as follows:

 Schedule of Deferred Tax Assets and Liabilities

 Net operating loss carry-forward

 $
 2,858,356

 $
 2,364,249

 Valuation allowance

 ( 2,858,356
)

 ( 2,364,249
)

 Net deferred tax asset

 $
 -

 $
 -

 The
Company has Federal net operating loss carryforwards of approximately $ 10.7 million and $ 9.4 million as of December 31, 2023 and 2022,
respectively. The Company has state net operating loss carryforwards of approximately $ 8.7 million and $ 7.4 million as of December 31,
2023 and 2022, respectively. The net operating loss carryforwards are available to offset taxable income in future years, of which approximately
$5 million expires beginning in fiscal 2032. Net operating loss carryforwards incurred after 2018 are carried on indefinitely.

 As
of and for the years ended December 31, 2023 and 2022, management does not believe the Company has any uncertain tax positions. Accordingly,
there are no recognized tax benefits at December 31, 2023 and 2022.

 The
Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction.
The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2019. The Company currently
is not under examination by any tax authority.

 Note
11 – Equity

 Our
authorized capital stock consists of an aggregate of 5,505,000,000 shares, comprised of 5,500,000,000 shares of common stock, par value
$ 0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences,
privileges, and restrictions of which shall be established by our board of directors. As of December 31, 2023, we have 3,802,666,978
shares of common stock and 2 shares preferred shares issued and outstanding.

 Our
non-controlling interest's authorized capital stock consists of an aggregate of 505,000,000
 shares, comprised of 500,000,000
 shares of common stock, par value $ 0.0001
 per share, and 5,000,000
 shares of preferred stock, which may be issued
in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board
of directors. As of December 31, 2023, we have 3,802,666,978
 shares of common stock and 2
 shares preferred shares issued and outstanding.

 In
2022, we issued 44,500,000 shares of common stock for an investment in the Company's Private Placement of $ 445,000.

 In
2022, we issued 32,412,577 shares of common stock, valued at $ 691,520 for consulting services.

 In
2022, we committed to issue 3,000,000 shares of common stock, valued at $ 18,000 for consulting services, which were issued on January
3, 2023.

 F- 15

 NOTES

 In
2022, we issued 4,812,259 shares of common stock, valued at $ 67,399 for salaries.

 In
2022, we issued 149,402,390 shares of common stock, valued at $ 3,107,570 for a license.

 In
2022, we issued 11,000,000 shares of common stock, valued at $ 242,320 for prepaid fees.

 In
2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $ 1,313,772.

 In
2022, we committed to issue 4,054,054 shares of common stock for the conversion of convertible notes of $ 15,000, which were issued on
January 3, 2023.

 In
2023, we issued 556,632,297 shares of common stock for an investment in the Company's Private Placement of $ 790,432.

 In
2023, we issued 115,257,394 shares of common stock, valued at $ 176,911 for consulting services.

 In
2023, we issued 64,081,632 shares of common stock, valued at $ 110,000 for salaries.

 In
2023, we issued 389,304,825 shares of common stock for the conversion of convertible notes of $ 919,492.

 In
2023, we issued 60,000,000 shares of common stock, valued at $ 96,000 for land development.

 On
August 4, 2022, the Board of Directors designated "Series A Preferred Stock" and caused to be filed a Certificate of Designation
pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to
Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall
be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation's Common Stock, and on
all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all
issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination,
on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock
shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall
vote together with the holders of Common Stock as a single class.

 On
August 9, 2022, we issued 2 shares of preferred shares, valued at 0.001 per share.

the year ended December 31, 2023, the Company's subsidiary, Res Nova Bio, Inc., issued shares of its common stock to third parties
which represented 32 % ownership of the subsidiary as of December 31, 2023. Net loss attributable to the noncontrolling interest during
the year ended December 31, 2023, was $ 12,387, which netted against the value of the non-controlling interest in equity. The allocation
of net loss was presented in the consolidated statement of operations.

the year ended December 31, 2023, the Company's subsidiary, Campbell Neurosciences, Inc., issued shares of its common stock to
third parties which represented 48 % ownership of the subsidiary as of December 31, 2023. Net loss attributable to the noncontrolling
interest during the year ended December 31, 2023, was $ 231,369, which netted against the value of the non-controlling interest in equity.
The allocation of net loss was presented in the consolidated statement of operations.

 Note
12 – Legal proceedings

 From
time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome
in any specific period could have a material adverse effect on our results of operations for that period or future periods.

 However,
as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a
material adverse effect on our financial condition or results of operations.

 TSOI
vs Does 1-50

 Case
No.: 37-2023-00045520-CU-DF-NC; Case filed: 10/19/2023; First Amended Complaint filed: 1/22/2024.

 TSOI
has filed suit to bring action against anonymous online posters of defamatory accusations against TSOI and its officer and directors.
It is a Complaint for damages and injunctive relief and includes Commercial Disparagement/Trade Libel, Civil Conspiracy to Defame, violation
of CA Bus. Code §17200, and Intentional Interference with Perspective Economic Advantage. This matter is being managed by outside
counsel, Matthew R. Miller of Miller Law Firm.

 Shepard
vs Veltmeyer, et al.

 Case
No.: 37-2023-00043103 CU-BTCTL; Complaint Filed: October 4, 2023.

 Kyle
Shepard sued the Veltmeyer Institute for Advanced Biologics, LLC ("Veltmeyer Institute"), Dr. James Veltmeyer, Managing Member,
TSOI and Dr. Thomas Ichim for, fraud (Veltmeyer only), breach of fiduciary duty (Veltmeyer only), conversion (Veltmeyer), accounting
action and constructive trust (all defendants), and intentional interference with contracts (Veltmeyer, Ichim and TSOI). This matter
is being managed by outside counsel, Matthew R. Miller of Miller Law Firm. The total amount demanded is $ 1,745,366.27 assuming worst
case scenario but as of April 12, 2024, there is no judgment. It is not anticipated that liability will be found against the Company.

 F- 16

 NOTES

 Note
13 – Commitments and Contingencies

 Effective
March 22, 2023, the Company entered into a sixth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists
of approximately 1,700 square feet and the amendment is for a term of 60 months and expires on April 30, 2028.

the year ended December 31, 2023 and 2022, the Company incurred rent expense of $ 25,372 and $ 25,044, respectively.

 The
lease will expire in 2028. The weighted average discount rate used for this lease is 1.1 %
(the incremental borrowing rate of the Company as the lease agreement did not contain an implicit rate). Maturities of Leases
were:

 Future
minimum lease payments as of December 31, 2023 are as follows:

 Schedule of Future Minimum Lease Payments

 For the year ending December 31,

 2024

 $
 27,536

 2025

 29,248

 2026

 30,340

 2027

 31,476

 2028

 10,620

 Total lease payments

 129,220

 Less imputed interest

 3,663

 Less current portion

 ( 20,525

)

 Total maturities, due beyond one year

 105,032

 Effective
November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.

 Note
14 – Subsequent events

 TSOI
vs Does 1-50

 Case
No.: 37-2023-00045520-CU-DF-NC; Case filed: 10/19/2023; First Amended Complaint filed: 1/22/2024.

 TSOI has filed suit to bring action against anonymous online posters of defamatory accusations against TSOI and its officer and directors.
It is a Complaint for damages and injunctive relief and includes Commercial Disparagement/Trade Libel, Civil Conspiracy to Defame, violation
of CA Bus. Code §17200, and Intentional Interference with Perspective Economic Advantage. This matter is being managed by outside
counsel, Matthew R. Miller of Miller Law Firm.

 On
January 24, 2024, we issued 56,197,183 shares of common stock for the complete conversion of $ 39,900 for convertible note dated July
20, 2023.

 On
February 9, 2024, we issued 38,843,225 shares of common stock for an investment in the Company's Private Placement of $ 31,075.

 On
February 9, 2024, the Board of Directors designated "Series B Preferred Stock" and caused to be filed a Certificate of Designation
pursuant to NRS 78.1955 with the State of Nevada. The series of preferred stock shall be designated as Series B 5% Convertible Preferred
Stock ("Series B Preferred Stock") and the number of shares so designated shall be up to 1,000,000. Each share of Series
B Preferred Stock shall have a par value of $ 0.001 per share and a stated value equal to $ 10.00 (the "Stated Value"). Holders
shall be entitled to receive, and the Corporation shall pay, cumulative dividends at the rate per share (as a percentage of the Stated
Value per share) of 5% per annum, payable in arrears semi-annually on March 30 th and September 30, beginning with the first
such date after the Original Issue Date, (except that, if such date is not a Trading Day, the payment date shall be the next succeeding
Trading Day) (Dividend Payment date), which dividends shall be payable at the Corporation's option either in cash or in duly authorized,
fully paid and non-assessable shares of Common Stock valued at the lower of (i) $ 10 per share or (ii) 100% of the VWAPs for the 20 consecutive
Trading Days ending on the Trading Day that is immediately prior to the Dividend Payment Date.

 On
February 22, 2024, we issued 39,682,540 shares of common stock for the partial conversion of $ 25,000 for convertible note dated August
16, 2023.

 On
February 26, 2024, we issued 41,000,000 valued at $ 0.0009 per share, for consulting services.

 On
February 26, 2024, we issued 46,814,657 shares of common stock for an investment in the Company's Private Placement of $ 29,961.

 On
February 26, 2024, we issued 29,000,000 shares of common stock for the complete conversion of $ 15,950 for convertible note dated August
16, 2023.

 On
March 4, 2024, we issued 20,000,000 valued at $ 0.001 per share, for consulting services.

 On
March 12, 2024, we issued 79,307,500 shares of common stock for an investment in the Company's Private Placement of $ 50,757.

 On March 18, 2024, we issued 1,000 shares of preferred stock – series B for an investment in the Company's Private Placement
of $ 10,000.

 On
March 27, 2024, we issued 66,604,786 shares of common stock for an investment in the Company's Private Placement of $ 37,299.

 On
March 27, 2024, we issued 10,000,000 valued at $ 0.0009 per share, for consulting services.

 In
accordance with ASC 855, the Company has analyzed its operations subsequent to April 16, 2024, through the date these financial statements
were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

 F- 17